0000064803-22-000015.txt : 20220504 0000064803-22-000015.hdr.sgml : 20220504 20220504063142 ACCESSION NUMBER: 0000064803-22-000015 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220504 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220504 DATE AS OF CHANGE: 20220504 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CVS HEALTH Corp CENTRAL INDEX KEY: 0000064803 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] IRS NUMBER: 050494040 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01011 FILM NUMBER: 22889733 BUSINESS ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 BUSINESS PHONE: 4017651500 MAIL ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 FORMER COMPANY: FORMER CONFORMED NAME: CVS CAREMARK CORP DATE OF NAME CHANGE: 20070509 FORMER COMPANY: FORMER CONFORMED NAME: CVS/CAREMARK CORP DATE OF NAME CHANGE: 20070322 FORMER COMPANY: FORMER CONFORMED NAME: CVS CORP DATE OF NAME CHANGE: 19970128 8-K 1 cvs-20220504.htm 8-K cvs-20220504
0000064803false00000648032022-05-042022-05-04

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):May 4, 2022
cvs-20220504_g1.jpg
CVS HEALTH CORPORATION
(Exact name of registrant as specified in its charter)
Delaware001-0101105-0494040
(State or other jurisdiction of incorporation)(Commission
File Number)		(IRS Employer
Identification No.)

One CVS Drive, Woonsocket, Rhode Island        02895
(Address of principal executive offices)            (Zip Code)

Registrant’s telephone number, including area code:         (401) 765-1500
Former name or former address, if changed since last report:    N/A

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareCVSNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐




Section 2 - Financial Information

Item 2.02 Results of Operations and Financial Condition.

On May 4, 2022, CVS Health Corporation issued a press release announcing results for the three months ended March 31, 2022. A copy of that press release is furnished herewith as Exhibit 99.1 and hereby incorporated in this Item 2.02 by reference.

The information in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (as amended, the “Exchange Act”) or otherwise subject to the liabilities of that Section, and shall not be or be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Section 9 - Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(d)        Exhibits.

The exhibits to this Current Report on Form 8-K are as follows:

INDEX TO EXHIBITS

99.1
104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


CVS HEALTH CORPORATION
Date:May 4, 2022By:/s/ Shawn M. Guertin
Shawn M. Guertin
Executive Vice President and Chief Financial Officer


 EX-99.1 2 cvs_ex99x1q1-22.htm EX-99.1 Document

cvshealthlogoa.jpg     Exhibit 99.1
CVS HEALTH REPORTS STRONG FIRST QUARTER RESULTS
WOONSOCKET, RHODE ISLAND, May 4, 2022 - CVS Health Corporation (NYSE: CVS) today announced operating results for the three months ended March 31, 2022.
FIRST QUARTER HIGHLIGHTS
KEY FINANCIAL DATA


•Total revenues increased to $76.8 billion, up 11.2% compared to prior year
•GAAP diluted EPS of $1.74 and Adjusted EPS of $2.22
•Generated cash flow from operations of $3.6 billion
Three Months Ended
March 31,
In millions, except per share amounts20222021Change
Total revenues
$76,826 $69,097 $7,729 
Operating income3,490 3,577 (87)
Adjusted operating income (1)
4,483 4,205 278 
Diluted earnings per share $1.74 $1.68 $0.06 
Adjusted EPS (2)
$2.22 $2.04 $0.18 
2022 FULL-YEAR GUIDANCE
•Revised GAAP diluted EPS guidance range to $6.93 to $7.13 from $7.04 to $7.24
•Raised Adjusted EPS guidance range to $8.20 to $8.40 from $8.10 to $8.30
•Confirmed cash flow from operations guidance range of $12.0 billion to $13.0 billion
CEO
COMMENTARY
“Our strategy improves access to affordable, convenient and personalized health care, which benefits consumers and shareholders. We once again showed the power of our purpose and potential, building on our strong momentum and raising full-year guidance as a result.”
-Karen S. Lynch, CVS Health President and CEO
Q1 IN THE SPOTLIGHT
Increased quarterly dividend by 10% effective February 1, 2022, resulting in the return of $722 million to shareholders in Q1. Repurchased approximately 19.1 million shares of common stock, marking the first time the Company has repurchased stock since 2017.
Continued to lead the nation’s pandemic response by administering more than six million COVID-19 tests and more than eight million COVID-19 vaccines in the first quarter of 2022.
Invested nearly $53 million to construct approximately 600 affordable housing units in Denver, Fresno, Nashville, and San Antonio, building on the Company’s commitment to addressing housing insecurities and increasing access to health care services in underserved communities.
Announced that Roger N. Farah will succeed David W. Dorman as Independent Chair of the Board of Directors following Chair Dorman’s retirement, effective with the annual meeting of stockholders to be held on May 11, 2022. Director Tony L. White will also retire in May at the end of his current term.
Investor Contact: Thomas Cowhey | Senior Vice President Capital Markets | (800) 201-0938
Media Contact: T.J. Crawford | Vice President External Affairs | (212) 457-0583




The Company presents both GAAP and non-GAAP financial measures in this press release to assist in the comparison of the Company’s past financial performance with its current financial performance. See “Non-GAAP Financial Information” beginning on page 11 and endnotes beginning on page 22 for explanations of non-GAAP financial measures presented in this press release. See pages 13 through 14 and page 21 for reconciliations of each non-GAAP financial measure used in this release to the most directly comparable GAAP financial measure.
1

Consolidated First Quarter Results and Operational Highlights
Three Months Ended
March 31,
In millions, except per share amounts20222021Change
Total revenues
$76,826 $69,097 $7,729 
Operating income3,490 3,577 (87)
Adjusted operating income (1)
4,483 4,205 278 
Net income 2,313 2,224 89 
Diluted earnings per share$1.74 $1.68 $0.06 
Adjusted EPS (2)
$2.22 $2.04 $0.18 

Financial Results

For the three months ended March 31, 2022 compared to the prior year:
•Total revenues increased 11.2% driven by growth across all segments.
•Operating income decreased 2.4% primarily due to the establishment of a legal settlement accrual related to the pending agreement with the State of Florida to settle all opioid claims against the Company for $484 million, which will be paid over a period of 18 years. The decrease in operating income was partially offset by the increase in adjusted operating income described below and a decrease in amortization of intangible assets compared to prior year.
•Adjusted operating income increased 6.6% primarily due to increased prescription and front store volume, including the sale of COVID-19 over-the-counter (“OTC”) test kits, and the impact of COVID-19 vaccinations in the Retail/LTC segment and improved purchasing economics and growth in specialty pharmacy in the Pharmacy Services segment.
•Interest expense decreased $71 million, or 10.8%, due to lower debt in the three months ended March 31, 2022.
•The effective income tax rate decreased to 21.5% compared to 25.1% primarily due to the impact of certain discrete tax items concluded in the first quarter of 2022. The Company’s adjusted effective income tax rate (3) remained relatively consistent compared to prior year.

2

Health Care Benefits Segment

The Health Care Benefits segment offers a full range of insured and self-insured (“ASC”) medical, pharmacy, dental and behavioral health products and services. The segment results for the three months ended March 31, 2022 and 2021 were as follows:

Three Months Ended
March 31,
In millions, except percentages20222021Change
Total revenues$23,109$20,483$2,626
Adjusted operating income (1)
1,7511,782(31)
Medical benefit ratio (“MBR”) (4)
83.5 %83.2 %0.3 %
Medical membership (5)
24.5 23.6 0.9 
            
•Total revenues increased 12.8% for the three months ended March 31, 2022 compared to the prior year driven by growth across all product lines.
•Adjusted operating income decreased slightly for the three months ended March 31, 2022 compared to the prior year primarily driven by net realized capital losses and the continued progression towards normalized total medical costs, largely offset by membership growth across all product lines.
•The MBR increased slightly to 83.5% in the three months ended March 31, 2022 compared to 83.2% in the prior year reflective of the continued progression towards normalized total medical costs.
•Medical membership as of March 31, 2022 of 24.5 million increased 674,000 members compared with December 31, 2021, reflecting increases across all product lines.
•The segment experienced favorable development of prior-years’ health care cost estimates in its Government Services and Commercial businesses during the three months ended March 31, 2022, primarily attributable to fourth quarter 2021 performance.
•Prior years’ health care costs payable estimates developed favorably by $676 million during the three months ended March 31, 2022. This development is reported on a basis consistent with the prior years’ development reported in the health care costs payable table in the Company’s annual audited financial statements and does not directly correspond to an increase in 2022 operating results.

See the supplemental information on page 16 for additional information regarding the performance of the Health Care Benefits segment.

3

Pharmacy Services Segment

The Pharmacy Services segment provides a full range of pharmacy benefit management solutions to employers, health plans, government employee groups and government sponsored programs. The segment results for the three months ended March 31, 2022 and 2021 were as follows:

Three Months Ended
March 31,
In millions20222021Change
Total revenues$39,461 $36,321 $3,140 
Adjusted operating income (1)
1,636 1,507 129 
Total pharmacy claims processed (6) (7)
567.0 535.9 31.1 
Pharmacy network (8)
484.3 455.4 28.9 
Mail choice (9)
82.7 80.5 2.2 
    
•Total revenues increased 8.6% for the three months ended March 31, 2022 compared to the prior year primarily driven by increased pharmacy claims volume, growth in specialty pharmacy and brand inflation, partially offset by continued client price improvements.
•Adjusted operating income increased 8.6% for the three months ended March 31, 2022 compared to the prior year primarily driven by improved purchasing economics, including increased contributions from the products and services of the Company’s group purchasing organization, and specialty pharmacy. These increases were partially offset by continued client price improvements.
•Total pharmacy claims processed increased 5.8% on a 30-day equivalent basis for the three months ended March 31, 2022 compared to the prior year. The increase was primarily driven by net new business, increased utilization and the impact of a weaker cough, cold and flu season experienced in the prior year. Excluding the impact of COVID-19 vaccinations, total pharmacy claims processed increased 5.5% on a 30-day equivalent basis for the three months ended March 31, 2022 compared to the prior year.

See the supplemental information on page 18 for additional information regarding the performance of the Pharmacy Services segment.
4

Retail/LTC Segment

The Retail/LTC segment fulfills prescriptions for medications, provides patient care programs, sells a wide assortment of health and wellness products and general merchandise, provides health care services through walk-in medical clinics, provides medical diagnostic testing, administers vaccinations and provides pharmacy services to long-term care facilities. The segment results for the three months ended March 31, 2022 and 2021 were as follows:

Three Months Ended
March 31,
In millions20222021Change
Total revenues$25,418 $23,274 $2,144 
Adjusted operating income (1)
1,605 1,394 211 
Prescriptions filled (6) (7)
394.6 375.4 19.2 
        
•Total revenues increased 9.2% for the three months ended March 31, 2022 compared to the prior year primarily driven by increased prescription and front store volume, including the sale of COVID-19 OTC test kits and the impact of a weaker cough, cold and flu season experienced in the prior year, as well as pharmacy brand inflation. These increases were partially offset by the impact of recent generic introductions, continued pharmacy reimbursement pressure and decreased COVID-19 diagnostic testing.
•Adjusted operating income increased 15.1% for the three months ended March 31, 2022 compared to the prior year primarily driven by the increased prescription and front store volume described above, the impact of COVID-19 vaccinations and improved generic drug purchasing. These increases were partially offset by continued pharmacy reimbursement pressure, increased investments in the segment’s operations and capabilities and decreased COVID-19 diagnostic testing.
•Prescriptions filled increased 5.1% on a 30-day equivalent basis for the three months ended March 31, 2022 compared to the prior year primarily driven by increased utilization and the impact of a weaker cough, cold and flu season experienced in the prior year. Excluding the impact of COVID-19 vaccinations, prescriptions filled increased 5.6% on a 30-day equivalent basis for the three months ended March 31, 2022 compared to the prior year.

See the supplemental information on page 19 for additional information regarding the performance of the Retail/LTC segment.

5

2022 Full-Year Guidance

The Company revised its full-year 2022 GAAP diluted EPS guidance range to $6.93 to $7.13 from $7.04 to $7.24 and raised its full-year 2022 Adjusted EPS guidance range to $8.20 to $8.40 from $8.10 to $8.30. The Company also confirmed its full-year 2022 cash flow from operations guidance range of $12.0 billion to $13.0 billion.

The adjustments between full-year 2022 GAAP diluted EPS and Adjusted EPS include amortization of intangible assets, a legal settlement accrual, a loss on assets held for sale, the corresponding income tax benefit or expense related to the items excluded from adjusted income attributable to CVS Health and the impact of certain discrete tax items concluded in the first quarter of 2022.

Teleconference and Webcast

The Company will be holding a conference call today for investors at 8:00 a.m. (Eastern Time) to discuss its first quarter results. An audio webcast of the call will be broadcast simultaneously for all interested parties through the Investor Relations section of the CVS Health website at http://investors.cvshealth.com. This webcast will be archived and available on the website for a one-year period following the conference call.

About CVS Health

CVS Health is the leading health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and over 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists, nurses, and nurse practitioners. Wherever and whenever people need us, we help them with their health – whether that’s managing chronic diseases, staying compliant with their medications, or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system – and their personal health care – by improving access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Learn more at www.cvshealth.com.

Cautionary Statement Concerning Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation. Statements in this press release that are forward-looking include, but are not limited to, Ms. Lynch’s quotation, the information under the headings “2022 Full-Year Guidance” and “Q1 In The Spotlight” and the information included in the endnotes and reconciliations. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties related to the COVID-19 pandemic, including the potential emergence of additional variants, vaccine and testing protocols, government testing initiatives, the geographies impacted by and the severity and duration of the pandemic, the pandemic’s impact on the U.S. and global economies and consumer behavior and health care utilization patterns, and the timing, scope and impact of stimulus legislation and other federal, state and local governmental responses to the pandemic, as well as the risks and uncertainties described in our Securities and Exchange Commission (“SEC”) filings, including those set forth in the Risk Factors section and under the heading “Cautionary Statement Concerning Forward-Looking Statements” in our most recently filed Annual Report on Form 10-K, our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022 and our Current Reports on Form 8-K.

You are cautioned not to place undue reliance on CVS Health’s forward-looking statements. CVS Health’s forward-looking statements are and will be based upon management’s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. CVS Health does not assume any duty to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise.

- Tables Follow -

6

CVS HEALTH CORPORATION
Condensed Consolidated Statements of Operations
(Unaudited)
Three Months Ended
March 31,
In millions, except per share amounts20222021
Revenues:
Products$52,522 $47,387 
Premiums21,631 18,960 
Services2,505 2,453 
Net investment income168 297 
Total revenues76,826 69,097 
Operating costs:
Cost of products sold45,509 40,894 
Benefit costs17,951 15,704 
Operating expenses9,876 8,922 
Total operating costs73,336 65,520 
Operating income3,490 3,577 
Interest expense586 657 
Other income(42)(50)
Income before income tax provision2,946 2,970 
Income tax provision633 746 
Net income 2,313 2,224 
Net income attributable to noncontrolling interests(1)(1)
Net income attributable to CVS Health$2,312 $2,223 
Net income per share attributable to CVS Health:
Basic$1.76 $1.69 
Diluted$1.74 $1.68 
Weighted average shares outstanding:
Basic1,312 1,313 
Diluted1,328 1,322 
Dividends declared per share$0.55 $0.50 

7

CVS HEALTH CORPORATION
Condensed Consolidated Balance Sheets
(Unaudited)
In millionsMarch 31,
2022		December 31,
2021
Assets:
Cash and cash equivalents$8,442 $9,408 
Investments2,900 3,117 
Accounts receivable, net26,451 24,431 
Inventories18,160 17,760 
Other current assets5,530 5,292 
Total current assets61,483 60,008 
Long-term investments22,595 23,025 
Property and equipment, net12,844 12,896 
Operating lease right-of-use assets18,801 19,122 
Goodwill79,060 79,121 
Intangible assets, net28,543 29,026 
Separate accounts assets4,670 5,087 
Other assets4,877 4,714 
Total assets$232,873 $232,999 
Liabilities:
Accounts payable$12,738 $12,544 
Pharmacy claims and discounts payable18,572 17,330 
Health care costs payable 10,260 8,808 
Policyholders’ funds4,138 4,301 
Accrued expenses16,619 17,670 
Other insurance liabilities1,387 1,303 
Current portion of operating lease liabilities1,849 1,646 
Current portion of long-term debt4,217 4,205 
Total current liabilities69,780 67,807 
Long-term operating lease liabilities17,786 18,177 
Long-term debt52,063 51,971 
Deferred income taxes5,829 6,270 
Separate accounts liabilities4,670 5,087 
Other long-term insurance liabilities6,363 6,402 
Other long-term liabilities2,242 1,904 
Total liabilities158,733 157,618 
Shareholders’ equity:
Preferred stock— — 
Common stock and capital surplus47,677 47,377 
Treasury stock(30,145)(28,173)
Retained earnings56,488 54,906 
Accumulated other comprehensive income (loss)(190)965 
Total CVS Health shareholders’ equity73,830 75,075 
Noncontrolling interests310 306 
Total shareholders’ equity74,140 75,381 
Total liabilities and shareholders’ equity$232,873 $232,999 

8

CVS HEALTH CORPORATION
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Three Months Ended
March 31,
In millions20222021
Cash flows from operating activities:
Cash receipts from customers$74,192 $66,487 
Cash paid for inventory and prescriptions dispensed by retail network pharmacies(44,365)(39,171)
Insurance benefits paid (16,616)(15,456)
Cash paid to other suppliers and employees(8,969)(8,270)
Interest and investment income received199 222 
Interest paid(782)(876)
Income taxes paid(96)(44)
Net cash provided by operating activities3,563 2,892 
Cash flows from investing activities:
Proceeds from sales and maturities of investments2,570 2,177 
Purchases of investments(3,474)(3,131)
Purchases of property and equipment(1,051)(829)
Acquisitions (net of cash acquired)(7)(84)
Other(31)— 
Net cash used in investing activities(1,993)(1,867)
Cash flows from financing activities:
Net borrowings of short-term debt— 252 
Repayments of long-term debt(14)(3,049)
Repurchase of common stock(2,000)— 
Dividends paid(722)(656)
Proceeds from exercise of stock options297 212 
Payments for taxes related to net share settlement of equity awards(62)(3)
Other(149)59 
Net cash used in financing activities(2,650)(3,185)
Net decrease in cash, cash equivalents and restricted cash(1,080)(2,160)
Cash, cash equivalents and restricted cash at the beginning of the period12,691 11,043 
Cash, cash equivalents and restricted cash at the end of the period$11,611 $8,883 

9

CVS HEALTH CORPORATION
Condensed Consolidated Statements of Cash Flows
(Unaudited)

Three Months Ended
March 31,
In millions20222021
Reconciliation of net income to net cash provided by operating activities:
Net income $2,313 $2,224 
Adjustments required to reconcile net income to net cash provided by operating activities:
Depreciation and amortization1,055 1,126 
Stock-based compensation89 87 
Deferred income taxes and other noncash items(187)(166)
Change in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable, net(1,967)(2,093)
Inventories(400)879 
Other assets(352)(286)
Accounts payable and pharmacy claims and discounts payable1,974 576 
Health care costs payable and other insurance liabilities1,478 294 
Other liabilities(440)251 
Net cash provided by operating activities$3,563 $2,892 

10

Non-GAAP Financial Information

The Company uses non-GAAP financial measures to analyze underlying business performance and trends. The Company believes that providing these non-GAAP financial measures enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current performance. These non-GAAP financial measures are provided as supplemental information to the financial measures presented in this press release that are calculated and presented in accordance with GAAP. Non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP. The Company’s definitions of its non-GAAP financial measures may not be comparable to similarly titled measures reported by other companies.

Non-GAAP financial measures such as consolidated adjusted operating income, adjusted earnings per share (EPS) and adjusted income attributable to CVS Health exclude from the relevant GAAP metrics, as applicable: amortization of intangible assets and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance.

The Company’s Non-GAAP adjusted effective income tax rate excludes from the relevant GAAP metric the corresponding tax benefit or expense related to the amortization of intangible assets and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance and certain discrete tax items.

For the periods covered in this press release, the following items are excluded from the non-GAAP financial measures described above, as applicable, because the Company believes they neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance:
•The Company’s acquisition activities have resulted in the recognition of intangible assets as required under the acquisition method of accounting which consist primarily of trademarks, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired. Definite-lived intangible assets are amortized over their estimated useful lives and are tested for impairment when events indicate that the carrying value may not be recoverable. The amortization of intangible assets is reflected in the unaudited condensed consolidated statements of operations in operating expenses within each segment. Although intangible assets contribute to the Company’s revenue generation, the amortization of intangible assets does not directly relate to the underwriting of the Company’s insurance products, the services performed for the Company’s customers or the sale of the Company’s products or services. Additionally, intangible asset amortization expense typically fluctuates based on the size and timing of the Company’s acquisition activity. Accordingly, the Company believes excluding the amortization of intangible assets enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current performance and to analyze underlying business performance and trends. Intangible asset amortization excluded from the related non-GAAP financial measure represents the entire amount recorded within the Company’s GAAP financial statements, and the revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. Intangible asset amortization is excluded from the related non-GAAP financial measure because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised.
•During the three months ended March 31, 2022, the legal settlement accrual relates to the pending agreement with the State of Florida, entered into in March 2022, to resolve opioid claims dating back more than a decade. Under this agreement, CVS Health Corporation will settle all opioid claims against it and its subsidiaries by the State of Florida for $484 million, inclusive of certain legal fees, to be paid over a period of 18 years. The legal settlement accrual is reflected in the unaudited condensed consolidated statement of operations in operating expenses within the Corporate/Other segment.
•During the three months ended March 31, 2022, the loss on assets held for sale relates to the Commercial Business reporting unit within the Health Care Benefits segment. In March 2022, the Company reached an agreement to sell its international health care business domiciled in Thailand (“Thailand business”), which is included in the Commercial Business reporting unit. At that time, a portion of the Commercial Business
11

goodwill was specifically allocated to the Thailand business. The net assets of the Thailand business were accounted for as assets held for sale and included in other current assets and accrued expenses on the unaudited condensed consolidated balance sheet at March 31, 2022. The carrying value of the Thailand business was determined to be greater than its fair value and a loss on assets held for sale was recorded. The sale is expected to close in the second quarter of 2022. The loss on assets held for sale is reflected in the unaudited condensed consolidated statement of operations in operating expenses within the Health Care Benefits segment.
•During the three months ended March 31, 2021, acquisition-related integration costs relate to the acquisition of Aetna Inc. The acquisition-related integration costs are reflected in the unaudited condensed consolidated statement of operations in operating expenses within the Corporate/Other segment.
•The corresponding tax benefit or expense related to the items excluded from adjusted income attributable to CVS Health and Adjusted EPS above. The nature of each non-GAAP adjustment is evaluated to determine whether a discrete adjustment should be made to the adjusted income tax provision. During the three months ended March 31, 2022, the Company’s adjusted income tax provision also excludes the impact of certain discrete tax items concluded in the first quarter of 2022.

See endnotes (1), (2) and (3) on page 22 for definitions of non-GAAP financial measures. Reconciliations of each non-GAAP financial measure to the most directly comparable GAAP financial measure are presented on pages 13 through 14 and page 21.
12

Reconciliations of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures

Adjusted Operating Income
(Unaudited)

The following are reconciliations of consolidated operating income (GAAP measure) to consolidated adjusted operating income, as well as reconciliations of segment GAAP operating income to segment adjusted operating income:
Three Months Ended March 31, 2022
In millionsHealth Care
Benefits		Pharmacy
Services		Retail/
LTC		Corporate/
Other		Intersegment
Eliminations		Consolidated
Totals
Operating income (loss) (GAAP measure)$1,409 $1,592 $1,483 $(790)$(204)$3,490 
Amortization of intangible assets301 44 122 1 — 468 
Legal settlement accrual— — — 484 — 484 
Loss on assets held for sale41 — — — — 41 
Adjusted operating income (loss) (1)
$1,751 $1,636 $1,605 $(305)$(204)$4,483 

Three Months Ended March 31, 2021
In millionsHealth Care
Benefits		Pharmacy
Services		Retail/
LTC		Corporate/
Other		Intersegment
Eliminations		Consolidated
Totals
Operating income (loss) (GAAP measure)$1,380 $1,452 $1,265 $(345)$(175)$3,577 
Amortization of intangible assets402 55 129 1 — 587 
Acquisition-related integration costs
— — — 41 — 41 
Adjusted operating income (loss) (1)
$1,782 $1,507 $1,394 $(303)$(175)$4,205 




13

Adjusted Earnings Per Share
(Unaudited)

The following are reconciliations of net income attributable to CVS Health to adjusted income attributable to CVS Health and calculations of GAAP diluted EPS and Adjusted EPS:

Three Months Ended
March 31, 2022		Three Months Ended
March 31, 2021
In millions, except per share amountsTotal
Company		Per
Common
Share		Total
Company		Per
Common
Share
Net income attributable to CVS Health (GAAP measure)$2,312 $1.74 $2,223 $1.68 
Amortization of intangible assets468 0.35 587 0.44 
Legal settlement accrual484 0.36 — — 
Loss on assets held for sale41 0.03 — — 
Acquisition-related integration costs— — 41 0.03 
Tax impact of non-GAAP adjustments(363)(0.26)(154)(0.11)
Adjusted income attributable to CVS Health (2)
$2,942 $2.22 $2,697 $2.04 
Weighted average diluted shares outstanding1,328 1,322 


Adjusted Effective Income Tax Rate
(Unaudited)

The following are reconciliations of the effective income tax rate (GAAP measure) to the adjusted effective income tax rate:

Three Months Ended
March 31,
20222021
Effective income tax rate (GAAP measure)21.5 %25.1 %
Impact of non-GAAP adjustments 3.8 (0.1)
Adjusted effective income tax rate (3)
25.3 %25.0 %
14

Supplemental Information
(Unaudited)

The Company’s segments maintain separate financial information, and the Company’s chief operating decision maker (the “CODM”) evaluates the segments’ operating results on a regular basis in deciding how to allocate resources among the segments and in assessing segment performance. The CODM evaluates the performance of the Company’s segments based on adjusted operating income, which is defined as operating income (GAAP measure) excluding the impact of amortization of intangible assets and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance as further described in endnote (1). The Company uses adjusted operating income as its principal measure of segment performance as it enhances the Company’s ability to compare past financial performance with current performance and analyze underlying business performance and trends.

The following is a reconciliation of financial measures of the Company’s segments to the consolidated totals:

In millionsHealth Care
Benefits
Pharmacy
Services (a)
Retail/
LTC		Corporate/
Other
Intersegment
Eliminations (b)
Consolidated
Totals
Three Months Ended
March 31, 2022
Total revenues$23,109 $39,461 $25,418 $126 $(11,288)$76,826 
Adjusted operating income (loss) (1)
1,751 1,636 1,605 (305)(204)4,483 
March 31, 2021
Total revenues20,483 36,321 23,274 135 (11,116)69,097 
Adjusted operating income (loss) (1)
1,782 1,507 1,394 (303)(175)4,205 
_____________________________________________
(a)Total revenues of the Pharmacy Services segment include approximately $3.8 billion and $3.4 billion of retail co-payments for the three months ended March 31, 2022 and 2021, respectively.
(b)Intersegment revenue eliminations relate to intersegment revenue generating activities that occur between the Health Care Benefits segment, the Pharmacy Services segment, and/or the Retail/LTC segment. Intersegment adjusted operating income eliminations occur when members of Pharmacy Services Segment clients (“PSS members”) enrolled in Maintenance Choice® elect to pick up maintenance prescriptions at one of the Company’s retail pharmacies instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail/LTC segments record the adjusted operating income on a stand-alone basis.


15

Supplemental Information
(Unaudited)

Health Care Benefits Segment

The following table summarizes the Health Care Benefits segment’s performance for the respective periods:
Three Months Ended
March 31,		Change
In millions, except percentages and basis points (“bps”)20222021$%
Revenues:
Premiums$21,614$18,942$2,672 14.1 %
Services1,4061,39313 0.9 %
Net investment income89148(59)(39.9)%
Total revenues23,10920,4832,626 12.8 %
Benefit costs18,04915,7572,292 14.5 %
MBR (Benefit costs as a % of premium revenues) (4)
83.5 %83.2 %30 bps
Operating expenses$3,651$3,346$305 9.1 %
Operating expenses as a % of total revenues15.8 %16.3 %
Operating income$1,409$1,380$29 2.1 %
Operating income as a % of total revenues6.1 %6.7 %
Adjusted operating income (1)
$1,751$1,782$(31)(1.7)%
Adjusted operating income as a % of total revenues7.6 %8.7 %
Premium revenues (by business):
Government$16,195$13,917$2,278 16.4 %
Commercial5,4195,025394 7.8 %

The following table summarizes the Health Care Benefits segment’s medical membership for the respective periods:
March 31, 2022December 31, 2021March 31, 2021
In thousandsInsuredASCTotalInsuredASCTotalInsuredASCTotal
Medical membership: (5)
Commercial3,285 13,924 17,209 3,258 13,530 16,788 3,201 13,584 16,785 
Medicare Advantage3,169 — 3,169 2,971 — 2,971 2,874 — 2,874 
Medicare Supplement1,292 — 1,292 1,285 — 1,285 1,146 — 1,146 
Medicaid2,375 477 2,852 2,333 471 2,804 2,184 637 2,821 
Total medical membership10,121 14,401 24,522 9,847 14,001 23,848 9,405 14,221 23,626 
Supplemental membership information:
Medicare Prescription Drug Plan (standalone)6,022 5,777 5,694 

16

Supplemental Information
(Unaudited)

The following table shows the components of the change in health care costs payable during the three months ended March 31, 2022 and 2021:
Three Months Ended
March 31,
In millions20222021
Health care costs payable, beginning of period$8,808 $7,936 
Less: Reinsurance recoverables8 10 
Health care costs payable, beginning of period, net8,800 7,926 
Add: Components of incurred health care costs
Current year18,536 16,291 
Prior years (a)
(676)(652)
Total incurred health care costs (b)
17,860 15,639 
Less: Claims paid
Current year10,225 9,538 
Prior years6,183 5,767 
Total claims paid16,408 15,305 
Add: Premium deficiency reserve13 7 
Other (c)
(13)— 
Health care costs payable, end of period, net10,252 8,267 
Add: Reinsurance recoverables8 5 
Health care costs payable, end of period$10,260 $8,272 
_____________________________________________
(a)Negative amounts reported for incurred health care costs related to prior years result from claims being settled for amounts less than originally estimated.
(b)Total incurred health care costs for the three months ended March 31, 2022 and 2021 in the table above exclude (i) $13 million and $7 million, respectively, for a premium deficiency reserve related to the Company’s Medicaid products, (ii) $19 million and $13 million, respectively, of benefit costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets and (iii) $59 million and $45 million, respectively, of benefit costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets.
(c)As a result of the planned divestiture of the Thailand business, the net assets associated with this business were accounted for as assets held for sale and the associated health care costs payable balance was reclassified to accrued expenses on the unaudited condensed consolidated balance sheet at March 31, 2022.

The following table summarizes the Health Care Benefits segment’s days claims payable for the respective periods:
March 31, 2022December 31, 2021March 31, 2021
Days Claims Payable (10)
51.7 49.1 47.6 
17

Supplemental Information
(Unaudited)

Pharmacy Services Segment

The following table summarizes the Pharmacy Services segment’s performance for the respective periods:
Three Months Ended
March 31,		Change
In millions, except percentages20222021$%
Revenues:
Products$39,164$36,067$3,097 8.6 %
Services29725443 16.9 %
Total revenues39,46136,3213,140 8.6 %
Cost of products sold37,49034,5232,967 8.6 %
Gross profit (11)
1,9711,798173 9.6 %
Gross margin (Gross profit as a % of total revenues) (11)
5.0 %5.0 %
Operating expenses$379$346$33 9.5 %
Operating expenses as a % of total revenues1.0 %1.0 %
Operating income $1,592$1,452$140 9.6 %
Operating income as a % of total revenues4.0 %4.0 %
Adjusted operating income (1)
$1,636$1,507$129 8.6 %
Adjusted operating income as a % of total revenues4.1 %4.1 %
Revenues (by distribution channel):
Pharmacy network (8)
$22,824$21,893$931 4.3 %
Mail choice (9)
16,37414,2482,126 14.9 %
Other 26318083 46.1 %
Pharmacy claims processed: (6) (7)
Total (a)
567.0535.931.1 5.8 %
Pharmacy network (8)
484.3455.428.9 6.3 %
Mail choice (9)
82.780.52.2 2.7 %
Generic dispensing rate: (7) (12)
Total (b)
87.7 %88.1 %
Pharmacy network (8)
88.1 %88.5 %
Mail choice (9)
85.6 %85.7 %
_____________________________________________
(a)Excluding the impact of COVID-19 vaccinations, total pharmacy claims processed increased 5.5% on a 30-day equivalent basis for the three months ended March 31, 2022 compared to the prior year.
(b)Excluding the impact of COVID-19 vaccinations, the Pharmacy Services segment’s total generic dispensing rate was 88.8% and 88.9% in the three months ended March 31, 2022 and 2021, respectively.
18

Supplemental Information
(Unaudited)

Retail/LTC Segment

The following table summarizes the Retail/LTC segment’s performance for the respective periods:
Three Months Ended
March 31,		Change
In millions, except percentages20222021$%
Revenues:
Products$24,605$22,394$2,211 9.9 %
Services829834(5)(0.6)%
Net investment income (loss)(16)46(62)(134.8)%
Total revenues25,41823,2742,144 9.2 %
Cost of products sold18,76517,0421,723 10.1 %
Gross profit (11)
6,6536,232421 6.8 %
Gross margin (Gross profit as a % of total revenues) (11)
26.2 %26.8 %
Operating expenses $5,170$4,967203 4.1 %
Operating expenses as a % of total revenues20.3 %21.3 %
Operating income$1,483$1,265$218 17.2 %
Operating income as a % of total revenues5.8 %5.4 %
Adjusted operating income (1)
$1,605$1,394$211 15.1 %
Adjusted operating income as a % of total revenues6.3 %6.0 %
Revenues (by major goods/service lines):
Pharmacy$19,532$17,885$1,647 9.2 %
Front Store 5,3134,642671 14.5 %
Other589701(112)(16.0)%
Net investment income (loss)(16)46(62)(134.8)%
Prescriptions filled (6) (7) (a)
394.6375.419.2 5.1 %
Same store sales increase (decrease): (13)
Total10.7 %0.4 %
Pharmacy10.1 %4.1 %
Front Store13.2 %(11.4)%
Prescription volume (7)
6.1 %1.0 %
Generic dispensing rate (7) (12) (b)
87.5 %87.4 %
_____________________________________________
(a)Excluding the impact of COVID-19 vaccinations, prescriptions filled increased 5.6% on a 30-day equivalent basis for the three months ended March 31, 2022 compared to the prior year.
(b)Excluding the impact of COVID-19 vaccinations, the Retail/LTC segment’s total generic dispensing rate was 89.9% and 89.5% in the three months ended March 31, 2022 and 2021, respectively.

19

Supplemental Information
(Unaudited)

Corporate/Other Segment

The following table summarizes the Corporate/Other segment’s performance for the respective periods:
Three Months Ended
March 31,		Change
In millions, except percentages20222021$%
Revenues:
Premiums $17 $18 $(1)(5.6)%
Services14 14 — — %
Net investment income95 103 (8)(7.8)%
Total revenues126 135 (9)(6.7)%
Cost of products sold10 8 2 25.0 %
Benefit costs59 45 14 31.1 %
Operating expenses847 427 420 98.4 %
Operating loss (790)(345)(445)(129.0)%
Adjusted operating loss (1)
(305)(303)(2)(0.7)%


20

Adjusted Earnings Per Share Guidance
(Unaudited)

The following reconciliations of projected net income attributable to CVS Health to projected adjusted income attributable to CVS Health and calculations of projected GAAP diluted EPS and projected Adjusted EPS contain forward-looking information. All forward-looking information involves risks and uncertainties. Actual results may differ materially from those contemplated by the forward-looking information for a number of reasons as described in our SEC filings, including those set forth in the Risk Factors section and under the heading “Cautionary Statement Concerning Forward-Looking Statements” in our most recently filed Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022. See “Non-GAAP Financial Information” earlier in this press release and endnote (2) later in this press release for more information on how we calculate Adjusted EPS.

Year Ending December 31, 2022
LowHigh
In millions, except per share amountsTotal
Company		Per
Common
Share		Total
Company		Per
Common
Share
Net income attributable to CVS Health (GAAP measure)$9,214 $6.93 $9,484 $7.13 
Non-GAAP adjustments:
Amortization of intangible assets1,870 1.41 1,870 1.41 
Legal settlement accrual484 0.36 484 0.36 
Loss on assets held for sale41 0.03 41 0.03 
Tax impact of non-GAAP adjustments(709)(0.53)(709)(0.53)
Adjusted income attributable to CVS Health (2)
$10,900 $8.20 $11,170 $8.40 
Weighted average diluted shares outstanding1,330 1,330 


21

Endnotes

(1) The Company defines adjusted operating income as operating income (GAAP measure) excluding the impact of amortization of intangible assets and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance, such as the establishment of certain legal settlement accruals, losses on assets held for sale and acquisition-related integration costs. The Company uses adjusted operating income as its principal measure of segment performance as it enhances the Company’s ability to compare past financial performance with current performance and analyze underlying business performance and trends. The consolidated measure is not determined in accordance with GAAP and should not be considered a substitute for, or superior to, the most directly comparable GAAP measure, consolidated operating income. See “Non-GAAP Financial Information” earlier in this press release for additional information regarding the items excluded from consolidated operating income in determining consolidated adjusted operating income.
(2) Adjusted EPS is calculated by dividing adjusted income attributable to CVS Health by the Company’s weighted average diluted shares outstanding. The Company defines adjusted income attributable to CVS Health as net income attributable to CVS Health (GAAP measure) excluding the impact of amortization of intangible assets and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance, such as the establishment of certain legal settlement accruals, losses on assets held for sale, acquisition-related integration costs and the corresponding income tax benefit or expense related to the items excluded from adjusted income attributable to CVS Health. See “Non-GAAP Financial Information” earlier in this press release for additional information regarding the items excluded from net income attributable to CVS Health in determining adjusted income attributable to CVS Health.
(3) The Company defines the adjusted effective income tax rate as the effective income tax rate (GAAP measure) excluding the corresponding tax benefit or expense related to the items excluded from adjusted income attributable to CVS Health above. The nature of each non-GAAP adjustment is evaluated to determine whether a discrete adjustment should be made to the adjusted effective income tax rate. During the three months ended March 31, 2022, the Company’s adjusted effective income tax rate also excludes the impact of certain discrete tax items concluded in the first quarter of 2022.
(4) Medical benefit ratio is calculated as benefit costs divided by premium revenues and represents the percentage of premium revenues spent on medical benefits for the Company’s insured members. Management uses MBR to assess the underlying business performance and underwriting of its insurance products, understand variances between actual results and expected results and identify trends in period-over-period results. MBR provides management and investors with information useful in assessing the operating results of the Company’s insured Health Care Benefits products.
(5) Medical membership represents the number of members covered by the Company’s insured and ASC medical products and related services at a specified point in time. Management uses this metric to understand variances between actual medical membership and expected amounts as well as trends in period-over-period results. This metric provides management and investors with information useful in understanding the impact of medical membership on segment total revenues and operating results.
(6) Total pharmacy claims processed represents the number of prescription claims processed through the Company’s pharmacy benefits manager and dispensed by either its retail network pharmacies or its own mail and specialty pharmacies. Prescriptions filled represents the number of prescriptions dispensed through the Retail/LTC segment’s pharmacies. Management uses these metrics to understand variances between actual claims processed and prescriptions dispensed, respectively, and expected amounts as well as trends in period-over-period results. These metrics provide management and investors with information useful in understanding the impact of pharmacy claim volume and prescription volume, respectively, on segment total revenues and operating results.
(7) Includes an adjustment to convert 90-day prescriptions to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription.
22

(8) Pharmacy network is defined as claims filled at retail and specialty retail pharmacies, including the Company’s retail pharmacies and long-term care pharmacies, but excluding Maintenance Choice activity, which is included within the mail choice category. Maintenance Choice permits eligible client plan members to fill their maintenance prescriptions through mail order delivery or at a CVS pharmacy retail store for the same price as mail order.
(9) Mail choice is defined as claims filled at a Pharmacy Services mail order facility, which includes specialty mail claims inclusive of Specialty Connect® claims picked up at a retail pharmacy, as well as prescriptions filled at the Company’s retail pharmacies under the Maintenance Choice program.
(10) Days claims payable is calculated by dividing the health care costs payable at the end of each quarter by the average health care costs per day during such quarter. Management and investors use this metric as an indicator of the adequacy of the Company’s health care costs payable liability at the end of each quarter and as an indicator of changes in such adequacy over time.
(11) Gross profit is calculated as the segment’s total revenues less its cost of products sold. Gross margin is calculated by dividing the segment’s gross profit by its total revenues and represents the percentage of total revenues that remains after incurring direct costs associated with the segment’s products sold and services provided. Gross margin provides investors with information that may be useful in assessing the operating results of the Company’s Pharmacy Services and Retail/LTC segments.
(12) Generic dispensing rate is calculated by dividing the segment’s generic drug prescriptions processed or filled by its total prescriptions processed or filled. Management uses this metric to evaluate the effectiveness of the business at encouraging the use of generic drugs when they are available and clinically appropriate, which aids in decreasing costs for client members and retail customers. This metric provides management and investors with information useful in understanding trends in segment total revenues and operating results.
(13) Same store sales and prescription volume represent the change in revenues and prescriptions filled in the Company’s retail pharmacy stores that have been operating for greater than one year, expressed as a percentage that indicates the increase or decrease relative to the comparable prior period. Same store metrics exclude revenues from MinuteClinic and revenues and prescriptions from LTC operations. Management uses these metrics to evaluate the performance of existing stores on a comparable basis and to inform future decisions regarding existing stores and new locations. Same-store metrics provide management and investors with information useful in understanding the portion of current revenues and prescriptions resulting from organic growth in existing locations versus the portion resulting from opening new stores.
23
 EX-101.SCH 3 cvs-20220504.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 cvs-20220504_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Trading Symbol Trading Symbol Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 5 cvs-20220504_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 cvs-20220504_g1.jpg CVS HEALTH LOGO begin 644 cvs-20220504_g1.jpg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cvshealthlogoa.jpg CVS HEALTH LOGO begin 644 cvshealthlogoa.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover Page
May 04, 2022
Cover [Abstract]  
Document Type 8-K
Document Period End Date May 04, 2022
Entity Registrant Name CVS HEALTH CORP
Entity Central Index Key 0000064803
Amendment Flag false
Entity Incorporation, State or Country Code DE
Entity File Number 001-01011
Entity Tax Identification Number 05-0494040
Entity Address, Address Line One One CVS Drive
Entity Address, City or Town Woonsocket
Entity Address, State or Province RI
Entity Address, Postal Zip Code 02895
City Area Code 401
Local Phone Number 765-1500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol CVS
Security Exchange Name NYSE
Entity Emerging Growth Company false
XML 9 cvs-20220504_htm.xml IDEA: XBRL DOCUMENT 0000064803 2022-05-04 2022-05-04 0000064803 false 8-K 2022-05-04 CVS HEALTH CORP DE 001-01011 05-0494040 One CVS Drive Woonsocket RI 02895 401 765-1500 false false false false Common Stock, par value $0.01 per share CVS NYSE false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.cvshealth.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports cvs-20220504.htm cvs-20220504.xsd cvs-20220504_lab.xml cvs-20220504_pre.xml cvs_ex99x1q1-22.htm cvs-20220504_g1.jpg http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cvs-20220504.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "cvs-20220504.htm" ] }, "labelLink": { "local": [ "cvs-20220504_lab.xml" ] }, "presentationLink": { "local": [ "cvs-20220504_pre.xml" ] }, "schema": { "local": [ "cvs-20220504.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cvs", "nsuri": "http://www.cvshealth.com/20220504", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20220504.htm", "contextRef": "i5d428e9ffad14c938f185c1f2a76f635_D20220504-20220504", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.cvshealth.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cvs-20220504.htm", "contextRef": "i5d428e9ffad14c938f185c1f2a76f635_D20220504-20220504", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.cvshealth.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0000064803-22-000015-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000064803-22-000015-xbrl.zip M4$L#!!0 ( /0SI%2%U. 5JA0 ".# 0 8W9S+3(P,C(P-3 T+FAT M;>U=[7?:.+/_OG^%+GOO/NDY$5BV_$;;/">;D"S=8EI"FX4O.;(M@\$OK&T2 MX*^_(]LD ?)"VJ9)VNXYVV DZV5&,_.;D32\^>\L#- Y3U(_CMY62%6JH/_N MO?D?C/_YL_,>'<;.-.11A@X2SC+NH@L_&Z)3EZ=CY"5QB$[C9.R?,XSS=P[B MR3SQ!\,,R9(LKQ4F=9FHS#%-&3./.9@RAV%&B8UES^:V[6FVKO'=05U5N&NJ M)L&>;AB8.JJ+34]CV-%49G#;,677WG7KQ.&RPF7N>89'J:.8BLYL3;954V>Z MI&FBVV$&LX,91FG=GV4XY<[;RC#+)O5:[>+BH@K/U4%\7O.CP(^XF'$M2UB4 M>G$2L@PH4I,EHF+)P JI7+:STL3,3H)JG Q$3>5:0\OJ+OE_AWU_2C-6.0LZZ_4O%#R>L0TS=I,D.AJ;MG- M3=Y%(%G"DHR)?#FRU+^I-Q@5J?W3>G_B#'G(\-KXZK.-^:^,4I3F5>L!BP9O M*SS"GTXJP&#.W+TW(<\8$J]B_N_4/W];.8BC#)8M[LXGT(-3/+VM9'R6U?() MU_9^^^VW-YF?!7S/.4^Q6*^2*M$WM>*[-[6B93MVYWMO7/\5)\]%V71_E'*+= =!+?*;J?91WNO:WXJDME@YN>QUQ" M'5,Q/&*H#O%DIFN>IJAGA\NA7(ZI@B(6BJZY7V]$,+[Y ?_8'+5'1Z-^M[GH=]\%_;!'^Z./4F_1 M4EL+=]@;]>:]T2?5DAM*Z[ GOU>LH+>(9SWYT[P%__=/^V'[N"=9QZU%N]M2 M>J=-N14V2;OK#JW%OFP%AO1>[L][IXYF'7:"=O>CVNHV9OWPT\(Z'*O][C!L MC3ZJO; 3MKM'X];IT;C=_73N'A_Y]O$G#?J>][K#8?^T)5F+WMPZ[HQ;W6#< M&K46O=&86,>-.?0WZQ\WRG<^0U]JU.].?*O[;M@^/H+Q?E2L45/J'W^NJ[F)*5!.; MW%2Q)S%#)1HAGJ-4]B3QGT8-27E36V'J8_)X'S2N*[3N4< &OWA['V\7&[R5 M/$.GCM!+'O? SM@$,X5YF!/N:1)S;.8YE3V/!2G?8&MM58P3[O&$@YY*;U ^ M0BG5TUR? >-1KJ3J&:B!4&[Y=\-$K(OK>J8Z2UUHH;;:1-']59_E M$-)XFN1/N=*OEVNM6!A?LM:6#?%SY/4#X@?J.I/&C^O2H6ZR_O M+;]:;7T"Y(W=Y1/H_B0[!$2Q)P:%);"Q=/G>5=GE,-U;JBY+EL_+3FHKA%I2 M]9*,M6M:NP:ZO5#P.3GO Q5GI'+]G=(HA'Z$AUP GSJ5J[HZR5Y?^&XVK!-) M^K]*7G7O33IAL*;LI 8-%)^+=C9:$V/&+/ '4=T!(O*D4KR\+'?B($[JO^=, MD%Y[,$GLL= /YO7_=/T05JK%+U G#EGTG]T4C#7 GL3WBHJIO^!U8L \\>+ M8M ZM",,_'(21!;#_F0UNXU#=-+=[S9.5L?\#$=[TCCXU&EVFXT3M&\=HL8_ M!W_M@X9!!^U6JWERTFQ;3S@%>:LIG+)TZ$>#+(YVT6'UH HH6J7FQK!O7TK/ MD"U'[4X+/:*Q7'HH!=)[2ELY6]K*]G&36/(G"GV!W7HWM@Y;XN^H??IY;'6M M<:_;N[#DHV$K_ AV[S-U_X+QR,&Y/8HIC$$!NQJT1IUQ+_PHM1;B;TOMGWXD M+;DSM$;[T'=CWC\R9JV%HYX9GJ=Y*@!PDX'!HY++L TN$_P#$(8RG6BN5-DS M\-_KE@X]UW6UG:R L'<:5A=U&A_:G>ZS'^Z':9).&3C268Q.N"-<)T04U.X@ MHNZXKU#LH>Z0BZ)IXF<^=-R8.4- &QSM.YDH)J9"OQW+,F8'?%G!CA.PA1AH M$;!)RNO+#Z^7SD[A_N'\I=7U%SLE:59'VK9FOY MD(MA V$$C=]6E,KRA0ES7=#9=7DR0P1H<8W8 ?9HB?BUA/DA=S]U7]PR^9X#J3'/'J1AJMP\OJG MC44_/()Q-"[ZX;N1=>C(['-I>=_*"7M<*>Z='?JO[ M9PA&3CB)M'W;)-7-5T#6P2C6%*/8X-3S*P MS%4N4THRTV1W0W#T=NNGK7%GXU7OIYV&C,&2$BL F&SDDON(Y:B=,(=$7UPD1\A/TL18"

WJ,!!:J*A56ZJ$@29&KLO+M0=)C-DL?&7L53/Q9P$>A M$)N1$R< W?*-F9,,T,9!/(VR9'X0NZM01&R$B3A;QB=)?"[:>=$8I-T-@OYA M,+3")K6Z+F 0&%GXSF\=]WUK]!D4IQ6V1LZBOX%!8E6TVSYMR+W1 /H%##)J MS7MA$[!,4[;@^Y;Q8R!NI4=3A5B,E=6*:Q=L3ED4HE*]SM[+P]6W!S4VNHX-5C"#%@Z*>:^T$( SDCE/GI(@AJ5K4CWI55O M#KC<&<_^[E;B^\0Q]ETWX6E:_GD/ R OTD)\33!C<'$&:)E2 N"9N+*,J>II MV":$8EO5)-W3 +BX7F6O'7$D AJ'B7^^ :AW'W.C<859!_"QG73CBY?I-GU5 MW$DZDV6'NHKJ8(]H+J94)M@TJ8P9-SS9T8BA$ZFR=QK'41H[8YX]'9]RV]A. M/H"7Z^>'#7]$)_BK!&]VILH*-D/'6VVVKT9^M1SP/ 7=KG9'_OC=D(G^.D49 M#_AD&(,%C7*$O"M\@V JL!EB"6<@B"ZOHP=+R_)3* M8S _8[JI6AXFB4BU*!ZE# TN6IE?ISU%)6;?]A MQN1IR'XPY,X894..V 0@,5A;$5BRXQFR>1!?"+J+0L$=9."_D><'PG3X*=B1 MC$;YF^4+L1WX [:,3XF":YNY4V@'>!W- MEV5>'$#GXCT!TWT1ZTGKCT3.?9AR@#Y%OK"$J'7R=?1\1"UXFO@9D%R$OZ91 M&0!*-[T;.XX#FP'],N#BSZ&84_ 8JJ(6X?@ MV_SQNZE3^OJVF/%3R")")8MAV5SG,9I<.TC:F08<45DMA29;/4 JSHWN$!T= M''60K$A5J/A 3/OCR9"LT5?U%8,GA38@AEF,C7A&;EJ/6ER%"I6M3\Z:7F M0\*%I1%7TO*K%L+6)VW/$^C[E_2LF!QZ!C)"=0? .3$X@'-B>QB,$,6<29[C M4D7F.GNFT@-\QLXU1M]K>PAUL;QCO]I.EHJZOZ1I59J::3KER2^9NMTB26ERC606GA^/ '?<7+3%:E(,QYT_%[MN=Y3:-JZMH7'>=5JKIJ?O-S MM\2HJE3]YLU26E5,[5L7B3,*_.^G#8! MXCER_]""]AS5.NR1WF),>POH$\8,[\!W [G7W;@2"&,?^M:B/V[!V*W%6+)& MGT?M[G!DC0 :CJ"]T5AJ'_:'+3'&]>/X0%1'7'S"5-4IIAI3,9,IH"ZBF[8A MDFU1M[(GP#<(Q$D6.^-=-&$).F?!E*/_E:H201.1_F3X9:?U?\G)X\M):1P* MV_!+2+80DK5; *[D,-7P.%9DSQ.'MQ@V%69BV=2Y1%Q.->+EEP:?2@!^ BO] M'>S(TE,L[L:N1Q0$,GC!)]Z^MPBM748 -XH87"%8422&J4YED3O.P;;M$MTP M'$FU#8!BL%9Z<3(N+,VEZ_X%U]"?H0O?C%P1N.#(GB,GWS<&%WD,*)/GEQ#6 M-G7]%,$0.4QX((#]((DOLJ&(?TS$1B]+DK MZE-;N.*([Y*0QSD=#PHR_HBA\_+BW?''66_47+1":]P^/AI:AT>A=?INU.J* MS^-9[[0/8WX76F%O_>(=[1\>^2UQV4[^2'NG#:EU"G8R;,U:\+D-[_?#SV$O M[,G]FRZ-.JI"" /C1C5-PU0"QXHY7,8>U0W9E9GGF>3>T/L=UY%$_JQ'NX_T MY9IC-$TSWYM_A_M?9G4]D=[-$M7T[K"AXBCOC0;9WSA@-01SRP/NB&S>49Q' MVZ@\SP(N3'<$DX.2A)_[*;P'1IQ% MCE DS'%$[@%16>1Y=EGBIL4!+O>V4+^RPRY#_=>M<_6'4XZ7TO(E"8C*E5EY M*/!XT'MKR4PG<;$:Z@D/F#AVOY'>] K(Y)A$NGJ%V>"I3;/-5^[+B/K0S*SZ M96;687*U+@82H2)SU:^E9A=S#0/6%.5D^G(RV8PNT[<_K]W"FR?1S'B(Y*HD(X0Z/)T&67X9I V:J=PY M!?UR;7H',:A"4?! L/XTCE0[0BTV+W:(RT1EN_D-Q[\X"T#+'EQ=WBXJ^>*\ M@(L8:%-Q+08DDC/0WRR*0.$Z0N$F)9&$SA;*-!LFG*,\\1RH_ES!MUCB#(OV M%%+T6D7[H%DGY;E;EJVU#TZ0-TTB/QW"Z^#B\<(&"$=JZ-M^ADRS2G).B$(P M0E?WS@N_+O>CKG@)-2[S7+\(1HGTG/Z5Y%Q.Z6":)&(WOTRJ""67!Z33(2#/ MW,C:'%QYXP"DP@JD^=+^](D&EL[KL (%N:\WX#/;#XJ>E@NA',YNSMV5.4%+5S.# M%FR^RO;K3!8$$Y"A/ 1^ZY'5TL'?1=>G%&\>?]@5H 9@15!>#A-M#W@$2B%8 MS7F 1-+V*1@",8)TZ@S+(3RS57>W!C=7-'A^K56<(2ET7RF"Z4N84*X!3+'3 M@NZ?T(M@T8[[X,N'3W<9I4#&+G=*X:CG;U%U6Y@V[T5$N]>GK)Q\@NORQGC,^,\T9^9=@\(Z&65C9 M^Y"[1)W2)0+0>;.CAMP<_:[DGF;K88/;15'Y)8I/)(I$HD\?;/RF,SJ(833H M@_!^F@(S@*B)K!F'+&,H3Y:&<\?*R:N):!G*?_5[<(9KZPR./31A&?"]H[:1Y;^]U/G1M^ >H9(O/K/[-2['O\ M._63TK/<+I:R>].&B3L-YLAA4[')D:/](MM &?-(@4M0$!>IQVT^9($G8A^B MH=RPE!5$9&P:P3MY,$)N=N.CWWK8(O=!5^Y&,*M*I(W_[2!"552A\A M!WJ5*(\P6 UV:?=;(XTE!RN-4?1%88?6'(M9_&.*./?QGDE/TNYP,>):_ MZO25O]3T[.:TXCK]4#/[<_X">96W6/P< ! !C=G,M,C R,C U,#0N>'-DS57);MLP$+W[*UB=2VU>8@FQ M S1!@0+N@C1!/[3]I76;!L%FL_$W8U_(,HC#, KNOZY^.JC78VO&'P[0 MVTS6 WX<6'5&% QPNCZT;>X5D%I7/A5-8-,-I^'$0T1KR;).PV(HQN/(WZK<"][E]M 0XTH33N$4W^:& M!]Z_B&'_M*?%,/!.C\$94T#]4JR#')A]N>AE]^HUN#U@>SCT23@7VO&MI)>U M+>.%V F,R :>#M%?0S%,R[,1>*%%W%]*))6B_DL_!:T4+4C-0#T='V>@DE L M/-.^>&C:7S7)?!/(@'AF__ %K#HP%*A7^T0&KGYL#5>9^M>P*\U_G'&>^<3T+?_&Z!'+%]ZE,,O_!RE->%9^>_WEC>WB/.\9@]G!< X%X\PU M7F@6K/DAO/]@8.28R%+/@V/"D:E.0?Z=+]WY.-6>W$/>(%)2TZX^G;SA4:]_'%\9ID"8AH8E$-0X[ MQT)F5UM(V!$A(E+&:9)D9)@<)\8AYR)-A10FYT,(X[A+FO!0,S0&H8/)S$YC M,:=W/-?SON\_[Q_O\WS7O:ZUKNN^?VO]/O?W=Z]U"S\*&<#VTZ<<3@%B8F* MO^@ A-/ 24!<3&RK_4L2DA);DH) )"2EI:2EMTX963E9&1FHC+0T5 $*E9,7 M25IVFZ*"_+:M^ZV';(5O18F:O(RTC/R_+6$O ),!-( R"3%M0!PF)@$3$PX M< 0DQ3[IX!_24Q< B(I)4H)*B<:T+)=E+Z$A+@H64D(1-0;+^H'(##)'5J' MCTLIG;TDK1VYTS@Q][',OA,-9&77,9:.2<#U)%FHBNHNM=W[=?4.'#QD:F9N M<>2HYT\L[\'+0E:O!J)"H&]$W8S"QMY)34M/P=](S M\O(+"HN*[]TO>5)>4?FTZMGSZL:FYI;6MO:7'7W] X-#PW^]?C,^\8_)J0\? MJ;2Y^87/BTO+7[Y^8__]<^T79QW MLS4 !I'4.BRUX_A9Z4N12MK&B3([3^0^;B#+[C-Q92D'7!^#JNB8SNUG;Z'] MD^S_!Y;T'Y']#]C_0DQD7D2, )\!6$0%*'$"!?\.?CF^]UJ3+^6OF% MSO!N1ACK?PEJ>4^:WNORVTSGYS"8AI>F7)N8ATM9SV4T>&2R&9U,UVT#R96M MI 4%[5G*^X@;I6A=Y'85QH4S *2,=HY"FAEP@LL4_,H/-4F@6SZ"[!IH*1J M. ="-G]!0NT J\[\\5,W^T@@C/1Y7]E?#=6UA,D3: VTV89ISK+"FY.RVXY3 M_!YMR@NB61M/45G] 9_6@TF]VLJ]M9+69HE/\/S)$5=&VB M Y/5XR>$@*2AB/]),*X>3S90]1AG,K'GYW'J-3G;O"O)7)VQ:L2QF>R7;P_L M,1;_J77#_9!:A">(=WE'&)B\T^[JS%BC@$9?YM%=)-IU*B(\8ILD5O MYC^$C15F'$=CU'9UGAI[-M-;8_&II[$#%!,"C+R+BGY*\7B!\C36/)F+64S! M71:\\VM%'^9QZ_?/MBW/J(.I6/0+GC(_#XG*H>(75%-Q5^Y=+AT>F7M TZ5W\Y&U/NUZJHKZ81ZV<(5[(Y\LFWZ3&A2O'FJXU"'O<+=DCUV-R9",-S M;"_MJMUF!;&,TJ3D8@2G&Q72Q?RYB>>$BIPJF,4ZB"[NW_TT>+8J!"$@:Y2Z MQG?_A4#XLVDMGVK>[+TC%6!7\F0FL?W!J)\R5D=4#BD)QG8,]"ZP=+ $GF3F M>$Q7/=S"L:6A_N'$N\D7-+N4-TQ38GLV?8HYHU#[-O<9HJM^0V)NF!D5Q1 " MH-Z' 9<46*1BEK5394CNW6T+$=7>BXF?Y8\5)FWF(JZ=*.$B.#=%&?E^Q:GC M&-FWSMRJ2F]&2V(H0P_WY@_=,MT=E@TW]*OE$D)M64V<=E$@!G3E>K&8R^DK/#F-?"?S\CG^"X8;SL;E X?*WAR&;NBC-*]R8/-F?K;%Q M+Z=S"GBBU0L!0$VN.V9$(+N?170%P]G?YV:3>*K1_/H;3'57,(9/BD&U>7=[ MQM M*L=<^W*7'&!]VKSO?6R3:G1T85N:#_YL8I/!+_S?U,WV'J/Z]2H5\C#.Y>>O MNN4V3@2_6@@$BNKQ0'%RBR+!KW4]1Z"%Z9Q7)403.D<1Y)N]GR'-U!6RKE74$0%Z\AY(4!( M $"GRB^;57TN.\ ZEVXG-T=?CWE-2T>KM)X,BX=6ZC5W2I1O6.59J&Y)\TW*YG^O5=?S9\+RO>=SW.*Y<'(IN MK^U9F5DQNC>EIN&0>/T^'=C/]7XCT"*J]S#6H(&MF-$5S;[(Y12]G)@*G27\ MAIEU]0T8=CM42:,?_JW-_"_&$UL=EWO=K@.\7^S9E4#6K*<0P$L)9A+,V?2& M6@Q^OG!-8,A:OQ,M^RLTG:3#W1G42HX8_7P",G'F>+;.?D^CWQ\!"0]0.):K M@>H<<>4KUP@DS"L75>K=Z0FF6B,?TW"7O"10X34A'@F6ZKK-A];;O/+/A,$!W&/1;79V+I M;OKY;U)/#)A7W[WN[-+OU]:V$L>HRX!#<(S[W3J3^0,&SS$CWBS%9#-DX_['])0!1MG!P_5*OT(Y())HYD X[S(6K(([K*<4YP "A/5W")H,>>W$]/9 MNZG_)SA]VNF\TV15>("FI2;")?1>T8]3J)3\:9WW:HXJ>R+#\HX"_"O.ELLV M^*FR!Q\^KS-]N;LP%@(9$EL(<,+!+*YU6SI6Z1(;,;^4PUH8$J@5#UAFDRHQ M#RGGE-)>%AHNWR4\@^@,?.L57SXJH;#9LX=A$P)D>\HW,(\I*F^68JWUT_:Y] R581NU%N(YJ7(U]P:4QEAV5_&=C8WA05CK^ M5TC&XJ#_UP"MU^Z^\+-]78&EUW[H>M96U^E4E,2[N73)F1_X?.4,^%$3#?F+P4>N2Q._?&QLO2SO#5N-5XM^YUI#2%MT."\V:, M=]2BOR:.\)1E.S!=V80?BKMQ,#U^$[UNA[)_6C5S7 ]@$S1*D9KM&K?SO.4,;Q]EL)^Y5W[G(_X =D'L5GV5Z; MNWYKYZ$X^T_=Q5-T/"W2@G!_*2:IR,_7KV[E?+)'MUR75-7X[4=6E1WT#Q?(TQ/CVW\491A#DT(S$OJ.8ED M/(*S',M4.1W\[&9XVJ8\IUNSF[7[0D]J9=$Q#F=IE[PVW4>A3R^3J?^HT#^G MA1.&)@57EQ=<>G[PF<'^EY0'&-+ T<(S^\-L;4=3P=V^-Z;\WJZ0ZAS7D= P M)"-_MK7J-@_V#&LR'J'G(OYMA^4,]2.F]<@:X>ZR,=S@X5%WG=?Z#ST5\MMW M."=0^$DX1JF?$I)10FS2RXFFR'N#R.$>#6N/*4>5XMAG(X&/R1 WYN'XFC?& M13!'TU1>O5J>CEP*70@\6G/M^[QVX)Q[P'1HZ*NL]N+!VE7+7HKAB^<35>:5 MR*N2JN8MZT1?=PI>M!-)$@*-PT.4CX&<@Q,)"E@?EN@/;SJ-%+^/JV\Q4/3. M_[/4G>O+9RX.$]5/$&0S1Z%:'O&]#5;VY+FG_)*>$!2.T=K 2Q "J3A6C4!Y M$W-!H'S);?YUR4\NY/O3M6])1DV!S(3CR"\#&[$+;Y?--DUL;U4MZ2VMKRQR MK023<)8]2=$3O, JGAM.P@6[).*F5<\+9-.^#P7V;:XGDUX\12TV=J 8)8AG M@45V![4%[/2;85+VY6L?A8#_*H'8NKJ"8N?W"H&6\YE89%0D.\TLQXFUG!J6 MVYR#CSR9;F!#L;+3'%WL>W>7@G >,F:E9!Z*,.)4[A3;6&9->&T5/]8:=+C* MRO[>BY2*GH6A;I[]ZD%4N\I.Z:&N0K6U?7U0"A$15[H^RMEH:L?&A?V%MN2G M]##RKA8DCSL7_$AQI.X.KKZ8>8P=QY'CEZZ@K?>QENU $EOD2/K=3_(TSM[/:\M_;>5'YM-R#X0-3$1<"IQ 7S M'%;-W+$>W@&N@L=2O.[J<%0=;=6LS%@NM/-F;MB[R99<>%@&?/1[BYWRII3.TJJ2PLI':V-'<& M_V-4P[5QGSU!*^C\@&ULS5Q=;]LX%GWOK]!F7W:! M82U*%"46;0;=3#LH-M,6;8H.=K$P^)D(XTB!K#3)OU]*MA/)DFR2BE6_)+)] M?7GNL0[OU26EU[_>7R^\'[)8IGGVY@2^]$\\F?%7EE?>=R&7?WFJR*^][WGQ5_J# G!: M?^DLOWDHTLNKT@O\(-C^M'@5P(AR0@) %>4 44X!19"!0#')F,(LQO*7RU=1 M* 6)" 0J3A* >"0 49@"CB.:2,9)(%CM=)%F?[VJ_C"ZE)X.+EO6+]^<7)7E MS:O9[.[N[N4]*Q8O\^)R%OA^.-M8GZS-[SOV=V%M#0DAL_K31]-EVF>HW<+9 MGW^ C (7QY MOQ0GIR\\;T5'D2_D%ZF\ZO^W+Q\&AR2SRF*6R4R85& M7WLK'V[DFY-E>GVSD)OWK@JI^MTNBJ+EM4))*I005RC_/C38; 3\9\);=K$^ M [@ZW(_/A7$7IQ^?#>Z%GA_DX0$WAAD->75"O\7.=%GE) M%Q.<%D_#-" OJC?.]=%ZF,K1CLFT'F<]=3>@ROM29D*N9LN6:R\5;T[TT5S( M=/ZYD&?YMRXS\.WK!D0]DLDP)Q91E@-J+>0RORWX4YZ[7O0E+YVWJDR7S#)Z+9O84G#.OBXG86APC43EO 5I4Q4)>;/.0 MGB2XU"'4)"PE?WF9_YAI!YJ, %8'H#JHE;?'[:SSJ[XM-HAIP??0OK:8 M\5R[OBE!ZQ>H:DB;T,KCTW@C^"\"IVYHMMT[1>Q,PD' MUJUA_%9"[8W529MM3Y/)L3> I@+[#>Q%]RXKT_+AK1#Z)UWJJX)2?BH^%_F/ M5$.\8<)H4];(R8%88\3SPM[ FP.R_L^X+] MQ/!5\MM">X8!NTC+154?A"0AD 2BP@@P4*0Q($ 4.+ 1Y+ZB12F<\&V\V.3 M?PW*RY4'@W^P?WH;N.:J[["W7^AC.#FPMFWIL)+T4-Q.*NXXFTRX0V$TM3IH MXYJWWZ<+N:@MWHF";KFC#AD&>[(8](K0UG$V?3;AC=!-IC8R_*[UK*;*K-WA&.3YQJDUT9I+M%^ M&O?K=#0Y!Q:K)2]6@MT9NY-J^SU.)MV= 37UN]O07L1;[>X/R^6M+)I+*%37 MP4D202!0I*^,">.@:I !%%$_"ED8QBQP7)KJ#'9LTNZLNZP0/\\Z59=JZ]6J M401.O69EP]V8I:M!4IYC :OK_&]%?E=> MZ;%N:/8PEP$B"J,$Q#Z! "&I ".( "D%]>.02HJ,%[AVC'-LT\6Z/-U@]59@ MO35:VZ*]GUK3^GTT8=.4\K9<.93U.YD84>'W^YVXV-\97+?NWVUN/PE<%+3: MY/GUX9KEBSG$*HA\71M ?7D.D"0(,"GURP3&BB91Z >QJ>Q;GH]-Z&MPW@J= MN;#;=.V7LC,)A^Z0F<5O)=;>6)WDV?8TF2![ VA*L-_ 7G2;W=./6P9_HZ6< MAYQB2!D%W%=:?)&/ (ET"F8DB@71I7H@C<77.\*QB?!Q$_D*I:=A>A5.Z&_.M>7L HSCD"2 M1%Q?VBH.*(T04 %%"?(YB:CQOK&FXV.3YF,.J<#9I]2:*_-,:LO 5 ET9_!. M6;,9Z:AD63N:/$EQM;G]E([JS9]%9*>Y4+. TPXCI "9.ZHH50ZJ,P M!C22?N)'.E4&TE1J3G^A!N=5Z,RUUB)KO]9<*3BPU@RCMQ);7ZA. M8FLYFDQL??";8NO]W+6#^R'C>7&3%_5*4KW3\BR_S,\\S22[R-8'W@56.]3YGK?18M8TUEC)%W3 MS!7V3+G?<-''Q/B[+5I>?\ZM%GV!#=YGT6OL*OPO\C)=E@7-RH_ZMYZ'/ B1 MA!$@C%" ",* "!&!*.35/<\0*4'L--\>X$CE_@32JU#:BGR+1%-]NU,SC;1- M67$0='_H([2\Y7!B&?>'TU7P@)V]>*M'RBP^7^799L.PB@(:1[Y?[>50 %&= MK(F,*9 ^(4J&.!"^\4U1V\Z/3;0U/J\&:+W3ND// 0K5@PDJD0R$[ M";3C;#)Q#H71%.:@SM6P.\Y6FZ M#GA? *T6>*_!R,SZ.5^6=/&?]*9NP8I0Q2Q.&%#Z"""!.""4!T"AD'&(8NY' MV"FYMH8Y-DEN9X\56$^C=>IR]S)KF66=^9HXT9I2Y9YK>YD8GV[;;G].QNT- M;3#I]EN[RO],9GH>67S(A+S_MWR8!XA2)# $#/J!+JL1 BQ"&-"$"#] 210F MEKVJK1&.5/1KE%X-T],X;=6^3:2IT$?0,XW&S9EQ$/= ]"-TO>UQ8DD/!-15 M\Y"A^_,[WMWS*_W[R;I=JI.TP#0.@4"!SN!QH#,X27P@.2$(!J1ES[F7Q/T:'DO-@25LR8K3TSSZ0A_U1(^6P\F?ZM$73M^3/7KM MAL3;9/Q<'YV^V+R3KIX]?OKB_U!+ P04 " #T,Z14#WT8)ZT& #I, M% &-V&ULU5I=;]NX$GW/K_#UOE[&)$5*9-!D MD9MM+X+-;H,VBR[VQ>#'T!8J2P:E?/W[.U*2;=VDO4(DP-H7VY(IG9DSQ\.9 ML=[\?+/['U3NBYC^?'!R\^1=O%Q_=&C:&Y&7=F-*U M '5^5'3=JX4DE%"_K3EVL77_"W$6J43.?O!9YXO$4+]DI;X*Z!TL.#DT\P1>5V M%A4MQ55\NK(P%HKN[-)#ONSN?&KK)AK7+*F5E(>6/!X2(KBU1%$I2&9 \$10 M01.^ZWIK=XV&=Q&IP1VNJIL%WA@CPUG[H26FB\1/S^ >R'F=W4\_P"MQQ6+K8EX(^+6>>&?KFY3R1BQ:JH1F'L("YH[GZ'7 6($?_$0E>\ZUWG6 M8%Z%;N48$;^$F%?^;>E_P<2[#" HLT(1DX1 1**1!>D#L4IJ(96D69:.$OH= MV%X:X-/7P.NYW+,8WI9-WMQ_@%7>,E$VOYL-+*D/0!DP8FV[B5K)B/+"DRPQ M!C1X8X4>I(674'M)(9FN% 8S.0DEG"%7T13GN!O>_0KW2TB"2]%4(JU%-B23 M1,M,HJ@3H#;0(.2PC>Q%V%Y:$%/7PA N]RR&4TQJODUL[PJS6J8VH<*FEC F M 3JQ#*:49,! \PQ;=*%&T,@7Q%Z"R*8N MB%8]]D>'9L)WC MA_"]=*&FKHLQN)V$2$Z]QQ#4CV\7>0EL*05+F:2"2&FP55(Z$,4])<%HZ;V5 MW*LQZLL7H'N)0T]='$,YG9(PSO#C^WA5W9;+H(S.?*8)M\#;JDD2Z]$9:3,( MB1#:I\EXLO@"W&\F1?\AJG@EH5/21%<8O8^7L;K)2X=U$614*Q:(RQ+D17E% ME!"NG>\+;;@63)CQA/$->C]U3'AD.1JU4Y+(954WIO@KWW:%LS#@@5M*;"*P MWV*8]W2F+1Z&S%"5LBQQXPED![N?/"8\S1R)UCV+H\UZIQ%,9[?6GJ6*9H09 M:HC0D!$-*L&:R:>IX=Z'Q ^2P]=H_00PX1GFJZG;<\C;?S^+RW55/C50*I@, MRQU/P*58 J7MW%5Y1UA@J?>8RI($!H7]6\1^H9_PR'(0A7L._Z>8-PV49]5F M82DT)*J#>2,T6U<\.*@N>8_70P MX2GE0!KW+(++"*V" 0O;[C_Z]O&.^#Z@'4NI C"M@%"+V4T$CJ6,"4 L#R&D MTB=!V$%B^#YV/U%,>%(Y$JW3$L=Y75]#_-H7JBP6-YCH<*N31'C 5@C0*\Z# M9]PXYD".*9%G%O03RH1'EZ-2O.\-!=PU;HKWC-NKO"D 2R,0&$^&8 M)UJ@*UXI+2U5:/^PJ?:WB/WD,.%AY2 *]QS^JVC:QU<_WF]L56": ZI3ZXEK MGQ<5@J;$8C5,9!J<-T 3.K"AW('K]WS4A.>1KR=O(C_ZMW=N;

UE*\A-I/ Q.>.@ZF0/P/L)8_+SQN'$ MCJ:/-XMG5%[@B9.#QR_:E_;9^).#_P%02P,$% @ ]#.D5)8EVH!R@0 M4_\) !, !C=G-?97@Y.7@Q<3$M,C(N:'1M[+UK=]LXLB[\_?T5..GN.)%%V3]9R.^GIG)W;Q.Z9-9]F021D<8O'G_^15Y-4S3\=6;-T]/3_J3I4?QPYO[ M;V_P5?:;((H2IGNI]^KMK_@7^)=1[^W_]^O_N;PD[R)W,F)A2MR8T91Y9)+X MX0/YI\>2[^3R,KOK-AH_Q_[#,"5FRS3)/Z/XN_](Q?743P/V-G_/KV_$[[^^ MX1_YM1]YSV]_]?Q'XGM_?>7;7:?MM"RSW^D-;,]CU.[TK$&_U[59OV-U>O\V M8)!OX';Q3)(^!^ROKT9^>#ED^/TKNSU.KY]\+QU>&:W6+Z\6[DO9C_22!OY# M>,5'"U<'49C"*&)XJ_A1O'SE$VL>]4K_WOLCEI#/[(E\BT8T_+]: @)RF;#8 M'X@;$_^_# @&G^:_/F7$A/<$?LARXAHF4O0O/QF=UO7JOV3Q?SE!#SM$8VF( MW;5#?/]CZ/?]5(RKU].-1>YNYVM*^P'+K_>CV&/Q)0P\H..$7>4_7'M^,@[H M\Y4?\L_SAW;A)$BIWA*2FH(4IE[^Y>RRSB^]2;W5:W9;[UG6QLLMW=AX;=MK MV[IAV =_*PRVTRXVV#><$((80.]D3,._ONI-ETZ?NM\?XF@2>I>9/'4\_'_7 M8^IYH)RN8$T1E),YW@9LL,*+D>]Y =NH(5S05BQ>O\8&_']'%.#;?]R1/][? M?+S_@WQ[__7+M_L[@U;&7]'JM\\\O7S[??;G]G_?W&OGVQY=W[\F'NX\WG]]IY!-]%@O=UL3V M _L1DH]K7MB:XG$44]P,R<7G?]V]_\M/;><:[WA-TLBCSX2&(0B3"WM;-&9X M)^QO,4LF09J00123=,C@_V+&R A&.4P("SVX^1.-W:'XL&6(+^N;^/"&JX?Z MJ9].>[,RV%W]6+WN<=2/N;OZL0ZN?@0;I%,_7!86E?;#SG,3[7#>%ZD3:V;K21&/=12@/85AY9.(%/^2'Z4PEL(VE$ M?NYV=(?T_2" 34HCDS$Q#-W\!=;$:$QC<<\X]F$K>F8T5DPY&%/^=G/SE7A^ M,$'']OW7.Q(-R,^&WK7!)O#(C?>_DV3^BJF;IJ+^X:C/0C2W@, N389D$$1/ M9!!'H]P,B\*$D]W2._GB>,%)7ZL11_3'I5"!';W;[?URC=&"W-3@?UC5F>N" M##NH6V-)8R_:9Q:0+OL+/,=_K;0Y:(.%=7C#S>CH1K>8X5;RD\9N;ZW78-N' M,(E?-.J,=A''L[SQMKOBZA6RW>ZYV_=)N'WOT>U#LXA[?@2^8G$*S;W@;QW%]FWK3KO M6*['D3B+NXI9 /KSD5VC:%U:W Q>(1PXA4*SDO7!EI<855AZ6T2.K6@K&W]> M7O>'F_Z*L2W3O+L=S3$[8J\\&@GP:DE2E K7+:F.9=6K)+D)DMSI::U>5TFR MDN2J2W)7ZYH]206YM%F7'7O(Y95N)?^7Z>&L'[K1B&WT",QRTUZ[YJ03/DNS M>ZV2PK>>QT=5E$N?W.AMU91'[6[9G4[QZ+0\NG"ZK\_!G*;XW=-#LVA)71\G M'_#(/OB%\?J%E(=MBV0-"ZNQ2&S-=JS=+!V)K/*Z\\ALM16/I.:1V77.QZ$& MN 3OLM0-1N,0AIP0V',(/V4B^^SQ-?/"U\U0ZF6#&3B5-Z.5P%5)X#IE%;42 M."5PNT^MI;?*'NXH7W1W7Q03."OI?IH;W,^]3>7JKO5U,Y1ZK6/6<.7]-"5P M51*X5EGS60F<$KA]K!GCW'&.Q0*JEVOXT3#P!\]5RJ\W'-TQBJ5KEWEMU]%[ MSAY9X)U&%4;R^N+?__SX\?)?[V^^D;_]^>'=S>?;]T7KKSM[IX-+5G&TOGI= MUHJC;^S1QYJ[E;JOAXGOT=!E),:$65Z3U]%[EBC.TPU+U"7!CRT[^YMI2UT) M5C&^4,Z6!7]M#4L?[V^^_:LP>H(\@;:750@O3.1:K'7]91+#E[&F]^&9 M^*-Q'#W"-R@8^TF"VH .!K Z<>%I,.WPD84^0HMAL35HE03ARN"C'A&@6:!Y M8KCQ:>B[0])G(1OX:8+/)9,1W,T?XX=]PRB )9_HY)^@A% ?T0?JAW M>L+B M^2$C8_@I1@45P0C'DW@<)4Q\-DIA!#X---*?^ %2'5[!;X.)1/#;*$+8LLF( MWQ[#1H6W#"9!<(G%^#,=2&% &6R,SLEA7)-B$GC,/89SY_)_@$@AN=/)Q^?0 M'6KS\#A?8D[NO M7^XY[$L)O)*UPG!ZHP;K4G. C?],: Q$#I[!XG]$4?=(_YD8K5\(&PR8B]%X M\COKQW ;_%D .6G92A;I:UR%Q"R=Q"$W,. M^0#H&!3A#W\$:A$&8?1T8_HT?Y2C'+C1:(1_2"/WNT9@#7S';^.'P0Q+4I(" M#>,:?85_B0![02ZR&P977VC,;S.EZ[Q>LUOR,3#XJ;^ULK/ M;"ISF?IV#__?^F!E118$&/0@SA.!)A,P*C;&D)ORN%\9W>N$ #T\-O)=%/\Q M;+0,EPKU1G[H@V,6^WP_C%$0*C9;L3S*,!)#M)$2C$B3P'8/WQAKY'40_C#3R&=S>1W@M6* H MS7<@QS=A&H5^M&@JSNGDZ3)"9>ZG'#87K5[/@W?RK^5?]6%IN9/83WTF%DN& M!X779N;RG!E,@%B/OBL6"X=?P#^@=PZ?PCG BY3&5PME?J'<3'$M00NG\,8' M4*N?=?([C>F0/(%LDV2"!S$>>4?!,B+_U,F[*(;OHC/S 81LS'B C-P.J<\U M,@K[;Q&-/?SEG1^#^13%B)(9!-$3"J^X4[QENAS =();<3EH#.W97*+"A9"']8K"SQ<;I\HF% YW.9T".0^ I/H(WB 0S]E M8FXT2*+LT[AH\$&@ GX034#XRM"'E3J)8[Y,63Q2ZT>*];,9$FO;R<\1SSCG M=AV0-+2CJ)L*%-G[(;PX@;\]#=DS^TS\/E^SM$< QMA M3@F!<0[%T1E:+&$47O)?!GY(0]?G&IPFDS@WZ$&[XJ.H_@/TQ+DI!&80V/B9 MP2_P+?TD"O.]9=F0&E.X>_:!,8L'?&MQL^V#!P0S%;[V-AU6(R-9>/)S/N3? MI[=^"/F=N1.$0;L^ Z:$F74WI@^,_$K),&:#O[[ZZ>7^!);QZJ2\6L'F KZP M5V\-X]1B6FT%7CAG84WDM+YER+#G3F$HF&*41"&#@ MSX2347>X14+)))F3S3F-B5IQ%($6]+BI"XZLT)K<^ES_KLUV['R/E-64Y$U= M4[+]J35[A/;!RINDFQ\YNKE2L%7)4M^/Y;RP8BUG[%?Y,\.I:8Q">MD'E_W[ M)1W _*YH\$2?DT4J'+$MS7F2%<#PX^8]!^W]G8?K_IZ%Z[YE#1-P!7_)4P1 M)O^ QP-\1?*2&80&?WM<*@>/;EXZ-3(2AW1?WK2V/97#[K-!E!N2 ?ZP?767#B M"D-9R7)=9%FA*"M9KHLLRXRC7!4KM+'QAV(BM@-6M$SH@@5G^3(F]/&61 E MQTI2]B4D9T79W2B[!7]9Z6\5F9 18_K(48K:84P7Y*("F:X$DQ3*M/1,.BO, M=%5V1^4Q;96ASRQ=WD3K97B:FF5LWVZ42;\K94US.^"@HNQNE'6VA\F4^JZ6 MPW0.$=K<(F$O/,IZ1M@K%$3?H4>"?':Y$KEJB5SI+@E*Y)3([3.W'?HD*-=6 M9M?V_#'CH_6".':8^(5>$/517!723R_V=CB]YZO$X9SB\$+G!24.31*'%_LB M*"/EJ$:*? -6=QY! %:0A$HBMIP*I6M]3?4,BR0KH2X_Y#(H,YT3(-VOK\7_ M/8HYFD'*RRQ'$2^S1( QCTQK+#FL5X9P() J.7ISC'A*"+?,(8=*X.ELP/U? M(.(96@&L)Y"LK0 6"X%RJ$)@CV'HYB_$B\&'"1$H%!SQIW1(J!M'24(HXLNQ M!X1]VP)-6)AGBD$;&;2<[4H\EK/(U.U?>X?GT$ZH&7 M1& 6P:!A[G[$\?P,A^N(1"<(7Y73 $%55O+$GBAB2\4(_ Y4B08#&"-*,(XD MEV]\D&[,-/-8XL9^'R[U&?;&0-P+NO!1.HK@ __E]QG>FZFXRJS5O@;UU6 5VOU;,XFG&FZCMY9LXQFUQ%,"L1AS'F-HC"(Q?00 M _DQ"B8CIN'MP<3+8;T3&O"%,H5#1GF^A"N7+A:V@VQ?Y%T5[F\S;++7'%Z9 M?/?31*#28V QC%:NO.+EDMTP/MD>*P_Q>C;9*T) M_6Q-D5BKHK0JR4_ZKMPI?CI,S MZTETBX#WO^4-G^Z$%;&AEY)T49[-@+IK9Y?;8>"#\)Y6O+74K*$>^$<37,F\ MUQ4+!I?Y'W+C\.9N9AR.F(?J2IN:9K"OP[O!@N\#_E8QQ+9]40(/ G17 M/9KMA0_81)HI9,#&E9.L!P4LFI1;3/ KFI^TIN1L3T)TRZ<$G8,2IJ49K5X1 MY:D0PN%9R![&;"3?H6/IY@.S.,=E?CN$WUU] MM?R M*@%IMH"T]// E%LY(\>CDNWS9WC1'9Y%\F^+I:OGS)U9J%,Z4 M\2]D8_]_*UP2MS%MKV)%51O+VDW=^:5LQOMFS(*M!?)9"C[!,1^B2EX)Q;&* M@6=5=DF ;PF>#R@B<]5Y4V$)&99? #W_"X^X=(RT)0$(#DNFM;\N?-,'\<4* MY.@A9DF"!\&MS O&YP$1NK8&H\]?,Y,#J@CU',"^H\L):":)Q#QG"U<,E!5[*2[[RT MT,4B1USAB#,#>UO*+2R"%8]_0Z"+D+]BBA2!^]EM-!JQF"-A]2<)2@!*AS>) M<\2,8DI,F]M,:9K&?G\BB@%!IPVB20R#RTO7>84B3'. *@IFJI31B07NZW1; MV2@_B-/SS/DW$Z1,"N>CR\;3*'C$H1= MXDA;?"EY$<.--R6>'X.^Y>@ ,6S,XRCD>SL-%U".A*Z?&KQ9S>_FU5!$]LM6 M[IZW//N.,0'*,QF/!?85$-4/N6(0^$TAP9)\\BLE($V#O[[ZZ>6Z?GL6[SC1 M*ELND1/A%:/SZQOZEGLKR#B\LC2[F#V K9:OESF-F)MXVTK72\A)(:%H'(B$ MM71>L1.(A-%Z]5:A2'!ZK@)1U09"8B/&%IK.C[['5A$DIC!=>3H3# 3$@C_$ M%P@'"8--@8W&0?0,QKPVQ8<(*-;2/LP,MNP>AM&!R3C#!IM=Q@TFB>+<$Z0C MA2:AT"04FH1"DU!H$@I-HK)H$OO K0J5]2_+WC$_(SWP4*H).7V@I!H+N44 MD(0"DEA@_4LSK7OA_^'F+W>RE=73[(ZQ6U9U&?TG<\=))6.9IE*EI4L MUT&6-<-N54J4Y;/B%&R'NO/\KD%5JY&:!MM1SV(*0^M8JN)%>B:U6UW%),F9 M9*JRI&KLN%6%/1$1N6FZ0-:C;QQ'+F9B>M7<=SNOR46WF8 G[4Y7W]&'DRCB M4'W2]::*2:>.AACZCG$]M?E6SMU=RFX0R:L=O=L^1_9^:R&?,63I4Q1_ MK^9.[#33 [8=NS1LD'*N3LVD=ENW%9/D9I+I*&2.BNS"^[O \NW"GZ@?$'<8 M^6Y%0]"]9KK!CJF7#6XJ!^O4/&J="9M5\:CX]GLF=%0)]C\)=M\57"RYT*]4 MX?R1AE 6N\K1.X>$KEJ'2S3[V/)9P6,43$9,RZ&#_) D8X;UZ>GS[%[>BCK& M?_UP$/#B"XW ]U.X;P&+: 8KXP:^*'%$V\L?8:FC*'97@ TGEKO-61FG%4$A M R"!$W@737 <#.0E&OENHN%8@HDWCS+C<6GB6""\W'401Z/L0VM:H.=5[\OP M"[SH=?Z;4?Q 0_^_F1#S5ZP(/*^ 3=@CS8T6%D*02>X4 M30X$C;H"D-+O+(8Q3!Z&&IHJ'K]M$$Q@F= $GII'"%J!"=/)^Q_Y(EQ\ M]>V7?WQX=VGTR"-U73_D(X"1I27HW-Z3SJ0(B8]85UY'K).>)%@GSMY8)QLQ M%C:+1.,@2^R#0)98K]XJR!).SV\LI7[PEY_L[O7'^]OZX)4LS2O' 1E,@H$? M!*C?6>+&_CBSRF#5"G3(;%.8@IJ,X2_X( ?,RK%%-'@?O@0V*[B)T"2)XC2' MILL@3'#/>H*[6 @F+ (AHCD7@N?-YCXX#] U-0MA/\'M$/;;X#O8 M3#,D2Y@\-SRGC^=7/)\^A!%PP24IXI>%#V F>B"^B!\6)PM[(!_5;,:Y%II] M/2)!!/8)/#@2 QM0%S9QH$R%8%;>*C"5B@&45&FL"DQ%@:DH,)4#6'_\C0I, M18&I*#"5JE%.@:DH,)52![2J:+\>1?MF6[,-IU)5^PJ 0LGR>EFV-+-;-B57 MR;*291EE63/L:HFR?%;<&2Q#^0:L[JQ\=9D"4U%@*GN J;14BV?IF63U5"F9 MY$PRC;+UW*J2K)+!N+/MN%\7$QO\(% (*I53$Z#)];+H9:HNZ=1,ZI:OW59, M.K55U%/58S)5C^5/K!0-G"F?=%-=60WKS39F5E2Q+F)-!5H/VX:?K )MSLP2 M]0FQ(% 4LVDYVJP]TX MU"%\N;_ER9GDNY^EAAZX%D+#7$I,0L7_SMKQ M+=; E2@36AQ>S# '0:2S^BX\GXHL5Y%!.]>;/?]PS/Q1?Q(G+.L;R))D@OF> MV#>6Y82=4FR&F0U9N,8*$X2U]N)OVHT=8G 6* M@_B[IB5_N:![\>1AKA9OIS*[%];$?+V4'SZ"^(L6R]D*S]*MI^6!&3/R$;MT M3/M9?K9:715:76M]]_GZ,^-4=7XO['ZRU?"-7R)<1Q7NR5:XUYXYG"=:=!L* M]WI[%^ZM+S8ZN#PTKMBO?9!BOXZ$Q7YG7.+KZP"Y;OM]$@27_T+U_[>)[Z&$ MUU:EW<]0%M"7]+FEA95K2 *^ W**_.WFYBO82KA://+^ZQUYR B3M3F'3>#G MCMZS^ ]=W; $P /\V+*SOYDVW_MBNND;4YMZP_L=W6QE/]BM[/V.;N1_LUJB M!B^?#0V2""W-@1^/UG_0I!QCY6)-($ M_ .P8B@)8*<)8/](4['-$K!RX@D-^+4H2;@1P^\F0P9&%6Y:&%80W@QL;& ' MC:/0F_/+4OH#!A^R@0\&5,SMKA"\%;YMS*P8/V4C,'BXU<4\(110G/W?[CCOPQ*W9=--1<%L.>& )MP#!CJ1B'^ K(9O:9S/ #24U2\I\) M>$Q@-,+#2-HZB-9Z57O/ H2,&8"7B$L-:?=/UH=%N5IV7;TIOZQMGT!U@$22 M(7@%**>4S!'#!8\99 MM=)1MX?M&,;BQ*7%X.7"K1:@^TLG%>XJ5S"'!@;Y& M>411F\ :X1IO0:2RLF2=W,#R ;%$SPWX/AG\X'UXXAZ_&KBC^ Y&K)H MD@1B1'BCCR81XTN#>_ES!=KXL@_9H,$L##*]FC W7_<VLO M QS@+@$75E(C,N)Z+Q/-1IO 6 M8HOGQL/GQ'=]RN,((BSG)[@=AQB62P2Z%O\9A@.[&_>A&"Q)\L\APV.(6& ] M#&&3Q5\R"H0,XR3P^!/./A@C&4:P5%.N)/PX)TD^0G@>_HY1"#H+[ ';Z0.G M/Y FQ-BCG_ 8HP;R0Y_Y%>!6 *-/Y]^]@&6!Z]U%,".N;0>P_CVN%]8!54PQ M'[*M>12!?@%M\,A"#H.!3A)G.9]2/E7ZZ#_0=('3 K_B&93D:#K%S$KPN=)) MN)L]?W=^VQ1FC8^7CUP#>7C*)!%&)+C?9V+[2./)5!<#8[B"0TX\ QEH"/> MS0836<3GP+T YTV\"#8,(O0_C 2NQJE&N$#C1\2+8#_2R4>X% KY 6W]]/2T MI)1KH#O6*\E;RC4#!4+H+Q:Q+\!N M$C3Y.6@;:AC"45R6/IJY*AH!(Y_?$$8I*/V1+QP%C7R"M?_Q.<0XH4V-EO7&V(-_&JF)K([_VZ -<6]V[MQE ;(@/F[ MEC_I+SD6+/1@"MDA2(Q&-\+6"+VHD]^>,VT4TI2?N: 2V,*(G"(/8%6"OF4" MKG$PP8<7HX)3BU-88J@))_W_!1L0S=383[Z+"Y,P\Y(R$S)CB^SRU">#=8M2&*OH["->%GX>)C([":\6$@.Q $!)L?/V6(DU'"S3J8 MS%AX?MDIVI8)>Q.6^X>;!KWD1D[#\V! >&SDN\MGX,!%>#4,C, WX@>6!5'G M J^/-,;=#%2^"/$+6R([H\(EE$:8@**1!]S]0ZZ+\JL^VA4\&IH(>7Q@"-@T M'N)0A6\J)IX+3X+JW4_%'[Q)3.>M]-D_%@"%B$B."5N-)X:5YFG M#5,'+V628/# 3X+9H4S$[8D!\Q!M2A.,Y1>$;36CGQ"A,8Q1@#TM3GXNA6"; M),S.5V'QH04WIQ;Q[O<_7 X/@'[@R =C!$9YD2WSN_>WV;)^C8% M%\]005@%O"^/NL-(R.] !?0/-+-FTS?ZUS^3QULDO4;\+^B"5>6KF ID A5,RK,@(). 1&8\""7+S1R M.+==3E?P9M6GE[N=CX3;T7D(09R2PI(2)CQ;.*X'/H>7;L:U1Y\]9?M$ CHB M.\*<'3EE^PNF.V7[R2SU8F[3T:9;#1V#/^!FGC_($9VB"GLT%7M6,@'K=OUL MP1Z&>Y"6?#@X+=A4)J B@;:3,;Y"[&\8,M]"$FWJT%"T=\06A=]&6-BY/5M; MG*"VI%70Z,&W/,'7CBG,1SKF*B;+E^0>V97 LL4@#+E<'7'!HZ[>J[F'U)'B M&EIW#G&D:)K5.%(\D51O\!I1I[R_^7C_!YB%W[Y^^79S_^'+9XD6XX9A1YBQ MQ'.E0!%CV3LW<.>\*E!B7Z9'9M+/Y^+/$$/>,(?7&\>:)7AA64Y[''DSP=R[M/.$@:R"K6Q 7NKP/K-1B^S5K-; /P$3=8-W635'NLN6V MJ;7-LH7+\J&Y**&KDM#978AM:Q MRJ(U*7R/$W/)<+1>IR4;EVJ@LZIM!><=]';2616&E]/:"JA1?B;9;4LV)M5 M8U7;ROK,TCFHAZSFJF$FE]'9L8F$LK=.IKQZ91U$96P='=[['(*PO?-/F2U\ MOVX3\BV1;D=SS++HG65I42$3K6[\[?2T5FDM>%[^UD!%5O $\U] MD"C+6:$Z#JR.6W$;B2KW:0=R4#E>PZ(B=EMKMWJR>=PJ+++$I9;FR-? H@8* MK-IQD=\R[!J^A38M'M+5>FUU!"4[E]I:MR5=(X#**2[Y!ER5.QMFTL[X87U+F[*F8Y&@]^1+X:J"[*A@'$J'R:#$:M(\I6[>(:M?2+&O' M?E?21,P/: 37C;^=MM8V=TS24A'S!ATJ?EGJ*J*.%6>TL32[5W8-J5/%"K&W MW56'BLJ8?$E./F3@P[GSV["0:-M1?5$E9U&GK5+$5#!44L+6PTSFP&K[F\@5 M5"X7MOE:GGB:"GHN<:?=DH@[-5!.E310>;>8/N)?L_DN-!S^&G%?5>ASOABH M9ZO(9YW9VU6!3V71%52:^ZO)ZMH.'4NZHDAEWBV=TY7>JI2-)_^ JW*G(JPL M&VP%O1)17LTW6>5^S-NGEE%VVU7N1X78:YH[9B8K]Z-![L><=ESN\@NDP+91 M<10$(B]#'#\V+>?VPI HL*G\$HF94P,-5FW[;G.?\J/M@77#+BT]?[GU UJY M97/Q*V;E*E%NBBB;9K4<-FGWP_R6G+YMOJ .;7$5>,<<8RP@O1=-<.\5N=%44F U,MS9L,K>WVCBNZIQ195["!AZ#4J3EH0TVDPJ>B?Z3_\(\0F%4]($)ESDAT21-4AKB/'9WD@\8ESGQ.VH@C-6V M;-8ZR6627"IXP&OL?H CD270 ";M>#2A]L[:QO0V.&(USTB!M6"6M2/EBX,U M@$D*HD_EW2O"UNQ.15A%V&K=J0BK"%NM.Q5A%6&K=:YL0E[B.__1 M]UCH)<1C;D!CYLWR$]7I?96/4EMZNVPO>OEB]DKD*B9R.Z(M-2Z@]X8G?<-_ M/?_Q[:_\'T&Q/E[,B)=?R]^6$=O&0X=QE/BI'P%E6$!3_Y%=/_E>.LPX,?^4 MH-)5:_8([2<1'@ML?&2.\"[#DN.#"U3K)8$R.>+-(BGF_\71^MY?7_EVUVD[ M+&TZF1,']AE/V;T^R4=P 2O M:/!$GY-%,HS\\'*>Y@7(Q>7TU49FKK#T^)1>7KK=M93FI0?O;S[>_T%NOWS[ M^N7;S?V'+Y\W2J(TPXY"#V&X/0(_\9(JBCDCO]& ABXC=T/&YFKEY9N%P^NG M_PSIQ/-AX-,Z:E$2,EW O/0'1A/0<<*N\A^N<^WBA_R=_*'K$8T?0&ZS58]B MNZ0U^:S%Y9E$ZRTAU9FYFWTYNZSS2TNZ7%SK.'K7L39>;NG&QFO;7FM8>J?3 MV>FUVZ]9CGVOLE3<17SB<:NT-B&1HJ?;-EFB7F M6"#OJVKD>,=<-NJ#)SFCB+% D28XUS=)P@[0>+Y0Y?"Y"_W*#[)AF3BW-!D2 M&L)<\0?VGXG_2 -8NBO*L,S\Z^;S5J_\R=%L6[HL%E5R5VN9ZVEVZXSI;0W+ M^/X0/K(D':U3U=/9US.EV-1Z+>D">BKO>[ESG6&-3PZRX&]>%R:0)B<'! M 0NN'S"-A"QM6(*UV='LME%YLZ?N7+(UVSHCEQIH*(1I%/NL:8:"X6@@8\I2 MD)Q+7:U[3BXUS%00;0+=21R#5B"4QP(;9B:TM;:U8]-L926BK\-,U$^1N'# M9UXZ^EM4Q9^=NP\,G7.!K#<)[Y M(3F>CX]1'>T>7:VPHVYJCEU]Z+T&<*FW8_-H9:N4#Z> *JR$D[-)=#?YAE;=S3,2KAC M8PK>!.B%/)]K_X.8"DJ=K76ZRFB0G$EMK>6H!,_39FTT,IY@:TZWK* I0^'D M3.H:94/#\MD)4JL D:&Q7@4<][1>.E(TM]&O98(VK'D:BA+FY@ASKU>V2]^) M?]OW 3WVV/^Z"+- *"CUAKNYN3)^QZ$Z!)E2Y M@-TPM:Y5_08M2N@J)G3MTEE5\KG.5='87X?AU'@L1@\>L,(\PGZ,$0.\:6\VQ?M8HN& *\>*Q?M. %&S-/"T@:J'/W<@>Z=NN$"=GM9U=O3:I=W:?J1AO:IM;J M*.@(V;ED:+VNZO)Q*G*_8P,&OI-'_-"-1HRD]$?CSI;:FF/N6$Y641NC@DSJ M:.8YP3T:9BBL(LHT]RAI%U@993:<7(>7AY515L-^>2G!'-Z^RE#I:%9I[T)9 M$2=GDMTZ8\52PZR(93717!O"U,P:]%6O.9,,K=>J?D6MU!I!'->JDY#U\M=V MM*Y5?D4L,,A_N845 'SXVT&RZLEF;8[=?*9)"60R;F M+%IGX5##K(5O+*7P1X\P&HN.QE- M IJ"7HCX&:(;C<8Q&[(P\1]9GJMX$41)LJ*DZ[XW&;V6,AVD94^O4[;X4U+; MH3K%G[?_N",9ZF:R,>ZLSAEG9.M:FK,K(JPZ9JP ?]M:J[MC#;JJN#HL+SY' M8*N$:1P% 5:"^F'*8I8TKAF?9:@,:ME95-K!D<]RD5H5"&M%F2B%MC!;,VQE MHM27OVW-A+YP1 M^>VO?7PLF^SR4QE];'3VQU'B(QKD5[3MMI66:_TQO8GL>HW>E9 M@WZO:[-^Q^KT_FTZK_*'AM.L[C%]8)?]F-'OEW0 $[RBP1-]3A;),/+#RWF: M%R 7EXS-S"PL",=;;=VUE.;!X_WNF-/ #2VJ. M?T]8M9%_.+NO\TI+J%M>ZINYT.QLOMW1CX[5MKS4,O6/T=GKM M]FN68Q]EL&:Q ;W@D;WH8?=6;EUC(PDI.I,ML+(LA)PY+W M4+5^HK$[)):A+5@'!6ET7N-PNOWQ-UYA7K#OOD@(,5B/N1$"*L)&#H8/B_&N M5V\_A,)2@F$$<&ES8'W.>"]A TDN(&;+- \UXR+5,+6BG%%F_=0B!,TM@@%: M!&001_,0I=0%6_HPC>:/5[=WP/*M$]3M5?O@DHM*S%SFC]-,6MQ) N-A\8J. MW?LT3+K9U[ES.)ZM]*H/1J&$KDI"U\$\9P70=5+M/::PIPTB;"#W" 98%#_S M0YYQS!(W!K6.YC(VL1^+2$+_&?1]2OV A"Q]BN+O9"R:WC,L'&J8)?AA"N[79R$;^+RE/6B6AJ6P7? .M1V5>R\QA]J: MW3X/AQIK7Z115J*33,;CP ?OD!L9;#0.HF?6/,O!T7J=GC(<9&:0V2U10:7L MAMWM!I'KSO4!NB!)BD>3>?4>CRT],J]A9H2Q:VJ'LB-.EH%CGC$ZUC!#8JHD MT)AHFJW0=4QE*6AW-5#=[>:BIX(*$G/'MJL<4)!Z MY7]F*7%Y)"&.'GU/G$&LRTE0I7%S=9I:>]<^(](42ZC*N,W.A^:4/IP_,T)X M6R&$*X3P/3/11'SHP)EHLB2;J7PRQ J/@!A>QNZ$!EG)Z8BFDUA4H$:#N3!A MTQ R3*VMN@S*SZ3RK'H&&99* M13JU1AC'&"I(15(CHE2,43LTS&RX,+16NX3L*9/AY*<(9HET$&4L[(X9#!I MU/DGY")D*:H('ERD>"6>KRQNR+;453:#O,QQSF/1O: 5\M+X,,+:VFT,/=6= M#;-P>,ODIMDP98QG9<"?ZO2S*NI^^?1SX(MS?82G$T1,,GD6=;WDJ(&H0JJAUQ_<;&]'D*-AE$X<.>ZJS" MT3Q#G<]*S!U+:]GGJ6G+W.=X!MFWUR8&GQ 136E9=#9#5!E MWGN4I%5XQ^R:JC)58O9TRJ#<*'/F,#GK[ >+75^8-MRF(9' MT&N8;6/VSI@"K:R;0BPRY(W;U,U0^)H'01!I4Q2Q\]8TC&-C82(:[ZI&$I:F M 6_.@0I$=%4C](G&7N,2VCO*N)"8.^5/U95IH?*\BD5)SY,*K8R&(NQIGQ&8 MK F'_BLY7NM._56.UT(0M=,N#]6H^B+X/7][%7:B?!AM9RRI_P2*.<#FCKU(ZU MI@9VD'RL;8*1=%M8&1&:$G"B2)\]^&&(5E0TX'\8PY>CIIW8&& K]8S=<*,J M:A-5D4NP:=@[@KKS=]/1N5'9! TB_PCE%6#1^< M2&>V'=5R4/?KG:KGWO7M#V]F&$?'\LFN_Q4 M1AT;CR_&D8"SN.+'B?XCF[6=Q\;HA90ZC!M8]Q17-;,5SY08S M#>@X85?Y#]=YYJ8?\O'RAZY'- 8?.=>5N#B6%!O_GK@\6S=Z2ZR=S%_(OIQ= MUOFE)64MKG5MO6=:&R^W=&/CM6VO-5IZN]?>Z;7;KUF.?9S!.H5>^X)/]J*G MW%NY=8U-)*3H3'O_RNKA@V;P<$E\HK$[)):A+=@#!6ET M7F-PNN'Q-U[Y*7S-?9$08K >M&TP=%N-=V!E#V$8PC&!KHN&C^R__0L%QLA UO5WY3K#V3#+,C[2Y2[Q+U*BBT.ZQ"O>Q3 M#*G#WC9F8;*[+JMN5HU3MG!!Y3V=FD-E*X85XGE]!EQ#.W+ XIC7\,QUKD:# M,L*J/@*TX=Z%G[)1T\ !+@RG!'2OLBA/SI[.>9J--\TTNQW2\(&7U\S%%9*$ M99FH@4_[?L!C#!K)FM7 =)F;9F C=*Z=C8I"%-X]>I*+Q8WKPE1XF,IE_B-F M9W#^-VZ7T'IE(-[5/G%J!IE:JTQ[!5EW"MGUP8?PD85I%.]9^5U%";/+X&,J MC_WD'OL9@RJ-,@DX$DQF&S;-#+#:)9"@E!%PQ)=TH65(@(A+MA\DDIJ'+Y@-.#3,R#,WN.BK306XFF;V:9,M)KS:$ MN[&O.JCN!G5AVRKN("][S/8906R: (_RN6CNJP)!4:@.NU'&TMJ=RJ(Z* P4 MM5I.7"KB]';LUG#^U;(> T4AG:Q!BS!:FZ%.<+B^]]=7/KBJ;:=EF?U.;V![ M'J-VIV<-^KVNS?H=J]/[MV6\>JOP45X YO@\1W#6F:&9+X$G M$[;UXRPBR"W'\)[TRA.LK\2X:<^ MX[ QQ1VC7>N>'=,DG?O@_"R>_!1S,1/B3N(8VZ_,7>3S>F',^,FIL4P3DDS& M8]'(!>[R9W*%0\2AK7G%&/[!!<%AW].A+_["&\5P%&9.1Q[(HX$[$B'X8PSRT=6_S&+;W!2GQ\.ZYD6X M\^J K7(P<8X\[!+E19/(S*GS)_*9M=DE1F-$UN5:(6MC=/'^Z]UK43V7 MWY6E0=,TC?W^),TYQ%&J1)":_7"#B<=$:B.N$13\1PI4XD,>,83E3#0<(X7% M!>8&O(.G/2[4Z'&!@647/O@\SCW+I\S"W9APK1%_ '][UL2J"IG/KXF>3/D: M!6$%,L7/0)))+%JZK=,J4ZT81OB&0<#<=.V-+VC2P\M=5?:C*86F\CD3+I[O M"M;>7!X]B9%)F;@DV^6%7P"U Q(^CD*Q <$;^BP$%9.BCF(_L"2*S??CPF=J M(5)\C"[8YA34+QX-QRP5).1#UH\K<%*)V^^X9TW!>U'-/;)XTUZKB3TZ"H+H MB>L\I!;?>S.I\V92MVUC O%T0=VA(NW#]Y9TEP9BZ-))LF"LS-M-[%D.,5K, M+7^9Z9G3>(D!ABO#62L&XD\^@OVE5Y=XTYD$ XE@=J;3._T0ELAEZT8;B;%. M/\XE_,\%8!_T 2+H,Q]1C\^AV4H0ML!GV-=E4(?W=3,-;M[K5P MWN'AH3_&NV!5P*KA]EV:F^^@HV !,G<8 OT?0*%FAG6,2?!/$;R>Z[5'&DRX MZ$]%EH\=IJ.3=\* 9)NLG'4Q6/ULVCF+T/VP%(YXAO!+ P!Y. X!O$ M![E;P?BVA&T"-'_->C4]#%A+VR+$E0*1A>:>9OLGN00DTCL##USP8Q+%M S,UL.C>N%TI-L)TRX=0Y7 M& 5&)^P!']3)#=AHT>1AN&9,G,5HU4T5U++@QD@,\:1" 3"_/=)$4N5&2/H\QK :S'@3PQ@E, M'-0ZK^6.!.]1SP@?''R=S218HSF>84C<(X/'@F=M_28D]KO,;R_ +ME\=T&: MW:(9'UY@T;(ED%N0FRT"=#N%MYYD30527R@B4*Y<&\3XQFS]K2/#TGMG"UL3 M0^?#6%AKPL?EW$N2")%-UBK$(4TRK<1VF]M+]/*3W4@V;R/-OU #7@;^=[;P MGFSN&GX-9T.Y^[!P?IG%%%#*0=A2'P,4<686XBOY1A*NKD\81X1[OE#[(K[! M>;BZ80R8^,+J2[CV?O03W*,VNWO*?CJ _?1N$N=J*^4HLJ.(H\@R1)$E'$)6 M'*A8AD801E1HP( ]X+J:]6$&TR>>P)^$B"7YO@/ZF:M%^@#O%D8 JB&\Q+&J M40)^A^G##JP1'N<6RR["/5< V&8?10@JV*K!A(O&?N1[>3JO)W9E/-B!L7.U M"")%L2T;F%DZ^3.SV4"FIH/0Y@,JMU$\S@!C87!!/BL"^\G2I^@#.(B@7\$C MYCHZ37CLS_=\BE5'N0)9GAC?+7^V'7L!@1;W-ECG"3KM<&_N?@K"#A@6L\*< MP?J!=9297C1??W"_X9!G1N,LFKR1'?O9067,(*&&!2D9-V)%>E1N&2G'J!H+ M.P+%CM9/MM^Q0%A[W)!;6MRPZX*MQ[>AWW(K042,\Q9]3(QBV9K!"?>Y+@-X(J; :8)%(Q_1 MZ_@BN!]2/\ 5?,&9U[J>_B&_G__=N'ZM97Z" M";\J;,)-KU"'O--#7F/S(:]\Y[6[:;$SZ:R'*/+X5O>$9W!CYOJ#S'^"?R)W M/L"[LC3$AH,X"YF*R(1YY4;RQ-!H%R&1S&?$P-XZQ2).>[3U1P3^O3@'LNR9#AT--U&E!,;2D.L7EZ=.$<3VS6H)_@<[$P0E W M#< *SM[$Q[]=P3[Q:)/P;\1H^)^Y4S 6FS@Z@/ .ENNA!($Y/?*?"5CI\&$8 M[FPJ6[]U6M-@N_97QH'+[N]R+"E.HA8#*27.V%%3W^2WO_]Z)\ZE MLIV/IAAO09 A#/R&BV>Q7.107:/*ST[-% MM#1NI /]2<@T3K9T:[7&?>+NG,U>=V MS9 KT8VQS)M.3>2IQ?=EZB%\X,90)6=3I*/FFO'7(V-REI,FW,>5U;/@+"YG M[9*++#62+XO7XLR]8+HOAKV"@&1QG*6O9HZD6'\K7^4A;7'#QB^4R3$3?,G^ MAG5+[0WB69EVJ):AMUOF,3J,&NUN1=JA.GJG,JU;NWJGN^MX3CW6GFXZFZ_* M-58#+EJ[O?8\@[6+#6C?_KU6H3ZV$G8976W@2Z;=>\E*\U;5PK=6+7R7O:WU M(C)W@(*V67Z&HKKZ[D+,KQDF(%+R+DL]593;_YF1\I0$UU^" MVZ6ADY0$*PF69]:@@YVR4'F-D."F"W'%Y/BBVRN/JBL-EJ,28B7$O-])RU9" MK(2XTD)L:7:O=6"+XE"B?,C^'%V]*WL/V)N7(!4:UHG#:I7%=E=].$[,(ON, M;3@4APIYC.:.8-&*12=CD6*0W SB!43FM6*3W&RR.V?LVW7(IE 5L%4_;@!C M:5AWJ-TT@^H2I=BDV*385%$V35&^%(MD99%:295@TUE7T@L6:UX*)0J#MW%5 MW5G-.QL67O^X!2BJ89%U6X6<).>0"CDI-BDV*38I-BDVR<:F U*E&)J9:&PU=&QVKH]:&6AMJ;:Q;&ZVV6AMJ M;:BUL5J\8K7:NQ:OJ%6A5D5-5\4>)5UJ5:A54<]58>]==7Z6M<%CA6\XANO; M8^(]*[C9-=<4W*R"FU5PLPIN5EJX66-A*U-PLPIN5L'-*KA9&2BIX&85W*QT MQ%1PLPINM@YPL\V*2E4>GLC0+$=6>*+3QEZ5*%=>E.WVH=%GE2@K43Z+*)N= M_1(KE"C+Q='&BO*%9>^-E>(C:X28B7$U19B2VMWNY(:%0TKE5=( MM$L),"T%HBDYB]IE_1'%H5,[C6;9[E&*1:=FD6*0W Q2%?*58%/;*6O(5KM$ M?BE-ZA+OO^IP._=<%JS[GXDO:M0O>8TZ\]"*90\B!PH(D\Q9L0NUZ(5DL[J8 MNU<6&UK.()HVI5J%71B%51*HU:K0JU*IJP*FS-+(VB*\':.!7Z MFTQO*O*5C+'ZWM_?>7;7:?MM"RSW^D-;,]CU.[TK$&_U[59OV-U>O^VNJ_R MAX;Q+-_I@5WV8T:_7](!S/"*!D_T.5FDPPAX.D_T O3BXKV9TX40"(^K*E8@ M+P@!/RE<7D;H@ 2V70$\\Q]HL_0SKQ?!C]ZYW6U=P\D C^X/GT M^MH4P&>,#*(@B)[PV !(3V+F1J'K![Z :\&*CI"E^8D"3=/8[T\$8F4:D=M_ MW)$,&0M^HSE+7[Z;AF".T,"=!+/OU"132U,R*.HI##<"X8WGLHJUK22TG=J:1.Y>VIA,AJW:D(*TL& M9P4133\7BJTH?%,%>O/JK:E9A@*%5*)< U$V]&[9="LER4J2)91D4S/-_?J= M*5&6BZ.-%65#[SB22K+RL63QL;: SRBPPNJ5:)=>\0H?ZL0L:NF6@BN4G$=G MQ?!2+"JVC.P="WPDPEFKRC;[D3W0@,!^F@8,FX 1ZKKQA 8[[:X5!D!Q=@QR M2.3\U9Q%L+MV%(_DYI&">U)L4L#[JYMLE"0$W%CAN)(A"SPRB&*2T&!S(D\] MC;O22&/*_#[Y/MLJ&R57/*J$ E=L:AJ;&N;,EH,'5[:>,LD5FQ2;J@*4JSAT M)/-5@1G+?ZY4A%6),(?8T.[I#^*/QM1-.<(#N#:\Q$ @.."17=,R M82ZL3GF4.Q7T.!E[6KK94?R1ES]&VU;LD9<]+=TPSL(?9;#(8K#LW[KQS/TM M7JZ3K&2G"[-LIXN7DNX;77-1I8(+4^O9AR[HE"DHJ"2X]A*LFTJ E0!76("U M3J]L[KZ28"7!\LS:U%N'+J4_I..7CR(?LVCS?FBOO< [YF:[!"X^/^-]OJ!& M6?E1-@%RZ)_\%_"G*8R*/K IY#*'EDQ(-$F3E(8XGR(P=SMG"JAL@RW=J,P= M*_$E,CVD>T=]A65''^QXK3/V;3PA"]#_#'U^,& N!O7(!Q&%Q /4;S3=W*N@ M3(>.4T]K6_^"+>-_=8#.)!7H=Y#"36S*[RSJG *_8^#W$A8?!J#Q_FGK@XT/ M\N8%AZ':@1A0F28'G9[>:^\&F[_MM8:EMYQ=$?=/C<;/!VL5>JV"XU\+-[\+ MTGRS\)D+]BM0R-;K*%>JDT$M',GW!??(?6IC]L.6D\]:-PV]+)K/"3#6SD&) M7XX:7&BB:+7U'>M(ZBU:#\2,3Z<_P:M6L.^L_ MR($]NM<)2=B#\.M&%+',_1#^,J;0"G\&;S=;U[9=WG_B/QO5KPAYI,('O)?RM^7BR MU\Z]+V;))$@%8AW\\C ):$S F/,3&!__&FIF,HR>>"OQ((A&.G=/?NJWD;IH='I\Z+DI M/9N8,*4U\C3TW2&!Z7@,2(_Y-1%,2,I]?$WA%^2$E;(L@$_$SV".3.-DXZ_X$: D$)6&$ M;Q@$X#.LO7'"6]@^X_"GS\Q3%0@PF,1\(!Y+W-CO\RH>PD(OC#!,;+S.N"-> M3"8)\GD3B?%]/DQ]',/O_A@$.Z,C3F0-Y\7]\+4A_I:LG0+M^X&?/B.%7+P$ M+QO3))U;//,O? *J$G<2QRM? F[0D ;/_V4O4P47(+S!2_357O8O)TZ<]\@< MQ)LNG9DC]6?DREB2O+BD,IF$-W'[C,-JI=AF-5E_4KYKVDAE3KG-GMYI[7;D MO/7@&!YL%^OC?OY3;D=W[*JX^<^^U_V0=>?_6>UQ[=H.^#N]!L+P0#< J"R4YK)'D'G\SGM M&]J #RF80N[S&3W'8@.]8_&CCY;C4:+C'7TY.+YV:6T,CF^/C=.78N.'ED() M5^8W!AYQ\)>?[.XU+LR/][1R$3-"/(%73.EIC;0ZP-^.W-7 MI%=5[P-_!#Z8R&&NH+KJ*W4%"W3F"N/RO.?><(W3"@NG\>YQ)'>P9-5CEBZI M0:I!5G^0!TJTDT0YK3^-G583D*+)\L>L<%;O4.\XRSL:U@*$6V(D9H\LG+"5 MP$Z92=<42:5*>"F69K1ZE:^N5T)7):&S>IK=J7Z7#R5T51(ZLZW91O5Q1)30 M54GH#+/Z_925Q%5)XBX,0S,=IW@)D1(X)7#[S*W;T9QS:CD%J=_P.T\=:)T[ M[\Q><8GW7W5XY.9,J_!F8YKP11 ER>MJEC0:^Y0T5K<&V-"Z;=7#77HF=:RR MVYYBTNF9U"J+,*.8=&J7Q6JU5;=ECME0S,WG98VNV4Q;(H,*P(6=/:[BMDZ[[:B]OY"!^D=S3)5I$!R+IF69G;+ M=B527#IUJ,!2@0+)681GFX:A&I_+RZ%.3VN5[B!X.F]4OL,K=>>9#P/W1S%5 MAX$5. RLKKG/&CE:'#C[4E4GMUHZ-!EI53EZL M.WN,;HFS6L6>DQ\&FJ7S'50NIKKS1.Z7? -6=RH!4'2$MP'#R"+(?>BQ,KR[Q+X<.%O<*M;*9 T4_^=>O%ZCBZ"T+J;"8<9WWS,D! M\LD4@#[O;N2'V"^*$3H>Q]$/?T13%CR3GRW=(7W17X&W%X(_V-,_P$MC#H0. MDGPYIL^B_!9 MKZ ,]&61@:[>-I$*\SCCN2@0-H_G/>OBY:^[]X&%>=(+1<; RN?=KFA*(M>= MQ*3/TB?&0L[O^6X5>:>*7+RT[=+'>\=Q\/A,=N;P]3_>W^:WZ61A1IO;>2W, M48ST:0C#'+%1'YY'P5T=RUWV6C?PN1Q?9#WIOM[=Y0_.6M.%<10$HN?8)^R/ MQT+>@>MV&,&[CB(&1U;0L"J[]O79!/C56V :[P87D;'O?B>3L6@\F!%V'/,V M;V/!4I2_<&.7N4PGC06'46+]$.2$>D)AN0P$6?3%&Z&2BB8/0_X>^%Z@DW\. MN3S[F> D&NE'Z7"#_*+R6B^K">]E%HN.B)LEE?[ MMVWO7]:\_JWM@_1OM5Z]5?U;5?_6===./=JU^^O=ABXBLG=[S'HG3D8C&L-+ MDA_<.?-O[)?:< MZO1V+#'62KC\YZ=I5W>,JK1*Q'Z9G5KQOV!'QXT9>;V56\_=J.C%/6Y3AQ[8 MP::8$07@(N3C9<-8>#NDX0-;X)2*8)]73=2]\:N&W>[9F#=.QQ4!_IEPS;DS M3<:1/Q_/Z8^G<9PB\#-%FA558V46[2MTJ!Y2M:)<$:@B^13$CGM/ 296C(,K MJ-$[S;5!!/NEDO+>! 2U;]F9WF*(8XM$-JQ98%5DM<+$K,0@Y>-XPT#?OL9L MY$]&Q;O:%<5JD6ZFFZV+DM TW?+%@N>8KVEH'<,^1H]2)1M5EPW#T7IV$3]3 M/OVL9'COGCOKIBBWO)I:IUL6$T9AH9U:J=CZ>: YSS'91KO>53%N\Q2P0R"8 MS^_N\B]%S6YU9,%MKQCEK)Y5R;5]: [7$S#&*(OQK2!]3LRAEGZ>]NS*BE A MLK5,^LRP\N:1)6E>A!.-V"'B*I7:&)W>,4))M2>;83N57./*Y2V$#MCN*7!V M>;EC]?23\T>9$><(1ABF;LIN1Q3LKW2HT]=*;9.FI1FMW2R,4Y]J5XNNO*U5 M)=7#&;SEPOROR 9H:AVS;,OFLJ2H4#"D;NR%3<^1C[O* #I'',60/XZ258O" M5)-T-_.GTH$ 1VO9*H:R$^G:6K?=K>025XYZ,3O%[*GT#LF99-CZ>1I&*H-" MULH**9O!??KM&[E8L#4(A?]/?D%DH;%(=YY&82K:&LYN9FLXQRJM@NI]-JQR M!U8$Y#RM V45$/GV*"7(A1K=M^1(4^K4JRRS/RX2>)#67%MO3TM-\2]3,$7V M8\S"9/7@:V]72;HY-ZV:R-(Z[2+0"ZI(IX&B8=E%$M&K:ZJK(3")]J(K,UEBX<_'&M%C.5SV=6*.]:WY"3=>JBG(L"4A'/T\Y MEJP"(I\R/V/=:(7>(1_?FA5;6E^3U0#?J^;A ZQC/TK.E!*-ZHN&Y;1JO:4J M$:Y19,DL6]2N DNGYI *+$FD#E5@:<6\56$E09=.Z85:[Z"!BBHMRT=7R8?4 MBESN8(XL[Y"/;Z<.*IVC#R)?5C<;>\%6,EWWJZQ*& KGH/Y/^)($;D^3U[ATOBUK8\KU# M/CF4FUZRO$,^OC7,DO];!*,)$59_'TNDHL&;78W,JL0?.YK1:Q_#.E>R47G9 ML+2>46]$/R7#I:8HM[R:FMD]3RF;BFJ4J2:S55A#&I6H.D>]O8U&(Q:[/@T: M!W?)/2 M?L#RI,9-8,2&,X4B?OMK'Q_+YIL_=7*ZF[P;U)"1010$T1.>7_.9D&0R&M$8 M7I*0%"[_P6B0#LDMC1G) (T3DK 'C)?]Y2?'-+K7"1DQ#T4)_COJLS@9^F-X M;.D0)U5M<2G.C,?MR M=EGGEY86I[AF=G33ZFV\W-*-C=>VO;:C=VQGI[=NOV8Y]A'&:K4[:JQ*!NHX MUDKL4D>Z\^Q\4O)_I+%VVH7>^D(8Y46KW6BOW+O&+A>;_IF,U>Y:8_43C=TA ML0R-F"VS2')[?4GQCKG6&IDRX6^NQ:YK M^,OJEK4H5(SRQ$RRN^?IP*A85":,W"X;BE!,.KVRLRS%)+F99,MW]JY8M*+L M6M*=/U]=*2\5?^?EKVEK;W#%10_%7?O[V M-,6TH]UY>_I@7K=TZ8,:54 ME_SLA:W)5)YA??D+6U/'W#$)YNC\S<)3^4#R@=N<>X<.,);#:;5@2EXTP?:K M$J/)JE&J4=9OE%6Q(^4ZB%1R)/LHUY[&&"5S;^4YCEG?&V56E[K8)=T/!U$\ MXCT.%SN&',724^]HPCNJHM3E"F*H=QSF'>O5>;OX]B.7.G\!;^!KS!(W]L>H MP,F[>/) O@8T)!=)2D./!B"OKQN6^=_16J7/Y"1.P%'O:(+0MK6N?+405=ES M*^?P->H==5VPG=ZYX97>I!21EO\[25)_\)S1 M[>VO?7Q3-H/E%V53MK'(<;6;XY/OI<.,'O-/B:%>M6:/T'X2!9-T\R,KC44/ MSM;E%J(K;#4%GO=2Z\FY?W&XOO?75[[===I.RS+[G=[ ]CQ&[4[/&O1[79OU M.U:G]V^[\RI_:!C/F/+ +OLQH]\OZ0!F>$6#)_J<+-)AY(>7\T0O0"\N+9NY MN<+3TY-Z)2+!27VS189J0:"#^,J3A M R-^2(:,!NF0).8O@]O38.RK%/.S$><:CT<=@78!'2?L*O_A.CZINYT.QLOMW1CX[5M MKS4,O6/T=GKM]FN68Q]EL&:Q ;V0F_^BN=-;N76-/7/2YMG% L3W?,%\$@OF M/2X8U"-\S1!8+F7::LL12)GN0OR-5SYH>M]]D1!BL!YSHYAO"%=@O[%8-*;^ M$ KM <,(X%)RJ"[MU1 0U)>J+_V.E#/.VI;^' [2'YMV:8WT&6Q_(>[4L+>/ MX?71"CI)B6.^'?*!I"/6S\>;O]QNM*,YK;(9NF5)<.9(KA+E9HAR5^M993/Z M3B7*#4/C_LB21&0S?&-^F$QB&KJ,QP2AQ#]ILNM43? M&8T;EIUF.%I[5S>QHKME%;G4T@P"B-N:.&%R9G(D+7\$6C[F22(Z3+-#5 MC7:!D:Q)?4'E?FGISIK#VSY-F#@ONJ!+9_0-<68O.MW.2M:QBC7(PYZV>1;V MG#K0,$V).36%!?;=9A.XFMJLOX\VJZGG;'0UIZ,B(_7E;UOK6#U)^=NP2,/L M5.&_BNST+WF<0,7OK(5#^,.='=T7B11BT=T+*I&V]E MQ=%OS*'$EW3(XFJ>/+CJY&'U%,^PBA_B*?.M,GS=K8E]Q>PWJ8VV+;GB+/0. MD27^TMY61;G%4'3I3M&E"%$'XZV*G'4T<]> U7$9>\B#KBHYDPA2'?ES[RDU@=%[90=E78&3[0&1;VQ%>N')Y#<"QAMNM+9;07>-.A):Y7"$-QKL#DY%^_7B"4H[,YIN))&9#Q7]A.S9!*D9!!'H_P\O\^P5C]A:1IDK\V_!2X0HD?2 MD$0@\'Y(@^"9,.#8"%^MUX/E?5E8WM7;)E+AQ6('9-$V2$ZR@L:)*)_\"8ZQ M2?O@X1+VPPTF'B,7_FORLV&1#(2//_-S-_]50XD9,Q=E,'C6A'B 1&TZ?9V7 M._PB%C'3\)D'8;O7"1%]%D#5CN/(F[AIHL$ ^ AZBR.8C6AY"&"']UD(7TZG MHNZB,O?R669V_"U2[#=Q9P+R_8#HM"C.*<$K0&"[O?/<;J-X MC$B*["\_V=UK<02U[]1*SJPFZ]Z59=WGJOX&9";7SQE&[QCH'@(#@,:H=M,) M,#>[=#^D?H#2U)\D\/H$%A+^.60@ DG"!3!)(M?G#'SR83VD0S^9WDV>&+R+ MNBYJ^ESM)_FC0Q:(/R44]05\!=\]]\+-D,&YK#Q1+KP!/.0/?*$0X'/Q!'YD M/\8H93L*( $I7P,]K)-B5$?3A6S1Y^368:?X&6^T]R#]\7JOWC:X/]Z+9G4S6]2=9[1?AQ0(ZSZ3.Q8_ M^BZ\^$Z$&J4:^\[!U-7I+4=2QRSFLH4!ZP-%4"O=+Z_=T[N&<_#8FJ/WG&Y% M J&.[MB%QU.);?S\- 53K+LKCT\_UK95+_ZKKHXO=W6L"B\;QL);WOBV3/_ MJK!,OCM58U/>V%3#;"L&GCT8?[@BP#-3S4YWGG'#FYU69>WO?6I7N-A1<@ZN M)/CO--<&$>R72LI[$X#@OK%'%D[84O1BA].%XT$%%SV^..$@Y9/5"A.S$H.4 MC^,- XK[FI47[(,(6M'RP4('M&NFVRU_\GB.^5H]S>C8^\#4[UJ8JF1#>MGH M:*U.MY+6HY+A0Y5'5ZC V=):O3-"5Q](YG95*A5)^G%*Y_P^J MV+9YYL$^_O>ZS5WZE6CVBNSM1W40JTFW=A%[6;YU?8:,U0KN3W99D&^%VW9B M#AD=?<>6=\J$D-6$V&+C5:&GDP 9B;-P_M&;_E5JN[1ZFMTIPNIK=:ZF0RBZDL[6V:55RJ2N?O5#,3.N5;M*@ BO2&QTJKB*Y M7;%GWX"S <'\+8Z2!.T)Q.ZL)@*,\1("3$F^568S-[1>]^SQGHI2KMMS*JF8 M5.Y#(?YV=^P@6]&H3 59U%/I*1(I$!D*0S8A'W=X7.;TK#-G]I% GB 7"]82 MXDZ37SBP]<*IU.OSV5%;FV;L;4?5TQEKZV7#^_5VQI2SKN1#ANU'ZJJP"KY# M/KXUH3GCES%#G(7P8=H]0I5VE8XG2*XUK6Y/U74IP5AWVM:I]8:J!+C4%"47 M5A4RD]P3Z>EE.VFKD)GD%FVU*[I6C=N-0;&==O[J!@T,%310024E'Q56Y7(' M?:@"2ZL&K@HK"';4AJ;H /6?LP2,SW)QB?(NZ0AB$+7O-6DRN)605[AWS" M*#>]9'F'?'QK.OB(Z 8YI/&(NL\D9.E3%'^O9@C>*1N"+VI42K\]JSSQ -4R*9$R.8\ M+<-4R$96UU]*J_T3]0/B#B/?K6C.3*^Q@,H=S>H>I4=[_4EG:Z:M()7K>P)N M:H9YGC-PQ:02J[!TQTZ5IR"YB53M/(4OZ9#%NQV#5+G/DMDI$OHXR1EBI>AF M.$7Z>LFWJI4#7RB+3K7\EIQ#=D>EQ4BD0"2)L9SY]-,-J#_B;1=DL=[A8Z4W+.=+BK>%281YW2*8KJ_%UR&ZF. MP:-FIRA6.1#BF'H19",505HA7$MO5U)AJ>!$(>-(-U7\2'86=57\2!H%(DG\ MZ#SL^1L+X4$7D1NP;QVB)\4T915.+.B^)A>&^9JHU *)[Y2%7K*\0SZ^*>^P MVJD%_9?\PGJ:5DY7V5;*]MXF(([*ZY5\ZSEC(*="[Y"/;^K0O3F'[O4\M-IA M(1_?5,"A$Q9_\T&-A>G6)-QU:1?0*D&FA\O'D7[]>()2CMRRDPOL? M;C#!/Y-TR(@_&E,WQ=9!MU_^\>'=I=$CC]1U_9 B=Q,MZR@TWE28CRV(8D;Q MI[;>_H5$(:'$:EUZ])FP_TS\1QH !PB(@)^0013SCZ;#F#$R@N$/$\* 1Q[Y M1&-W2"Q#(V;+-&%%P+AB^'L:\2?&L0_//C,:Z_40B[XL8M'5V^8N8@$W32. M=RQ^!$,^(0E[& %E__*38QK=ZR03GH?UJ1?DB2;$<73G%T)##W_J_0+BM%5" MA&4Q%1-\#GZ 7V,&[W91$07/.MDH(QD9;-12JRKLR??28;:USS\E;(RKUNP1 MVD^B8))N?F1.]%R@"(L/;J&T"@F:X2RY*7/_XG!][Z^O?+OKM)V69?8[O8'M M>8S:G9XUZ/>Z-NMWK$[OWVWS5?[0,)ZMMP=VV8?%__V2#F"&5S1XHL_)(AU& M?G@Y3_0"].)F7D:NM[_V<<];G<%)2;UL#';7DOIN,AX'#.4?9/Y#",INQ%?+ M1F&49> 7?X84EG[*O-64C_XRT]V]_KC_2WH'JYRI!KX M^J5X#WIM$ 5!],2U+)IQ))F,1C2&ER1<[2W-;5F=CEG,I2ITV70OG2D^O.Q' M7L)3VC8*'7SN =8D6FM+0()3&>7EIQ(<:W=T[N&L_%R2SSOEIVM4[W5UY?/JQMJUZ\?^%\/B+'GQO MY=8U<3.AZ\X42UK9UT0*'C=Y/PF3]SV:O+AW3?VB&D6::LO"VR$-']@"IUZ0 MYJJP3+X["ZJ)\_;8F?IH_(U7/G@&OONB((G!>LR-8NY 7$U &\0B@O8A%"XP M#",0GCC[X;)QBL8?K@CPR3:W?9X+D JK#JU #+6#,^M[!&>Z[911PA6'48"# M3+=(4+D^-#.:M)O4CX.;&\LID:_1.=VI$T7.<8*:=U5>#%KL<+*W453+BOPQ MCQ\/-4CY9+7"Q*S$(.7C^(&2X*O2U>1K''D3-UTQKLM,MZ(M/PME+&V!49,\ MB<>TM4ZK"%!(Z714)1N5EPU3LWJ-1MAK@ R7FJ+D\JJ9QGD*>U1M3?&^TZIC MGT0:477L>YOG;S6N9Y]C%NDPH)#U5KNZU=LF:G8)QT7[=>&=24'JG9HY+;US M:O8HPT$%Q=8RZ3-+B1\^LB3%/$6L!8A&C%P$49*LR.BNY*C,IGAAK"[,@WI# M_W][S]KDMHWD7T$YE913I>&*>LMSYRIGXF13:R=>CV^O[M,6AH(DQ!2I$.2, MM;_^N@%0[P>IT8@@B=0FJY% $.AW-QK=505:G2SW'\QC=>N>9T)PH]\J MIKN@15)V)#5M+5V#9(@)-RF*ZW(4A4)69QKSN)QU-5VWKGT>>XU>][PVV'5/ M1^DU6NUJFT'USGGHM(KI9&)1E*,+]L!6?35&@-BF)0=J<"G[2%6I(J\WK"4J M""7?8SPFWCB$^K$X.^IHH=5GVU'5],9:O=P!X&I[8]9=WR&0O*JJV@1BGJHJ M,/Y;HCG,PYLM=F5'EF)D'2JK_#%G6#XLF!#V#K?W7+>[)/?3 MNPVWWWR)F*$EC;*31JERKT4Q)6;36=8A)M3.55&S;<(A#7$HCAPMSL<)TI1N* MJ9J_[38Z@Q=)W[*D47[2:&6ZX6">:+8D_.PBDONV:#:YMMQBG#/$%N=CC'E#G,PUMM M+OV]&_V9B)B-2+BM@\MY _! XGH-G,C*QT'.;;1BXPN5)XVJ]UFQ)%RI$)F] MD6JX8^5V;?:500+1ALB.V.DV5J8OD=L4&QLK.T8?34L?1DMTLV-4ILQA'M[J MD(*5MAHGKQ\69$;_#",R"<.1^.&[3O]6J!9H!!\3/SZ[&_DE2S%=:0[SB-)L M>)DRAWEXJYE9_VE*HQGU%K8S>.;MEB4H.6QT,Q66RVT46-HH/6WT&X-!M9,Z M+0WGVJ+A]-KH=?JVE+392,K?O,(&. RW;<^[V2U-6 MN-MHN[8@\WFU1WH5[TM1[[/57M\>?QN.(K?C=.WQMS$2Q,;)WOX13UE4N_96 MW<'0]K8Z V[]IEM*IK:.;K:^TZYM"VXR>GI.TW8%-T%RV"#$V]]93'CPR$0\ M8T&Q.=X+560,?=]-BKG)=G>C^1U'_ZES^F66>;X0'O8 M<;)H=!M9V8%WFKFO:S>VZN;$MNWM2>O$'D\Z=CHVJ]54 M06VVYVC*'.;AK8"3LG1N/<4-CG_3D\JY*+]V+;.(/(9^4M;J^_U3QV75]+]Z MUO^R_ODQXS)WZ=%JTX=Y:LALO]B4.7B3%L/? M8OK@LU3K7%ZI]YR3"K1U3($>U9__SO//IGX]%/UP!YL2$5N-\/%"?<6#$0OB M-SKEU4NOK;;S< -7":;83"^V^>G^#7))XRPF=SZL78@>7N MCW_]]O.-.R2/U/-X0.5=L0:9[[LZEJ9*CTC7Z7U/PH!0TF[>C.B"L+\2_DA] MO+ .>.?P2!C)-\73B#$R@S5/!6& F!'Y2"-O2MIN@[2:K1:P 2PF@N_C4#XQ MCS@\NV T&6.[/V7UPN'_WW*][I#[J#9KOUT!N..Z,1HYW>L#U^ M&/8[[*'7[@W_W>V^2A^:1BL6G;";!Y 77V_H&';XAOI/="$VX3#CP"-3;1F-_+ZCOD_G<9\@UP"F_!2 ?9Y+!LM!PH0M__3\!!6D1 ML]&/.VL]QE3%K/8NC.8A2ATIJV01-G*OI)51J]_/CU] )(Y#WP^?I'1&FX^( M9#:C$4PBI,32 A(!^ZW7S?'GM2OD_] MO)(33E/)"AU1TV_6/SORIRU'5/W6'3I]=W#PYZ;C'OSMV+1#IS4X_.NQ68__ MUAYT+K[6@3/H9%Y/*3REXF':=UKM=DGPWW=Z_5ZE\'\BMGXR"C#<&;HG]J9D M74'QJ!V=I^YP22/ZHS*BWZ,1C2IMZ695*%I5613>36DPV4QA/$'-94&9>2,S MBHEB6[@L_36@AHB>:@#2(5!3NMX# "GSET[-O'IO' M: DB,X"K=KCY[EI\51ET: !BI!Y\7#XBZ2;+Q6\85;C4CK-$IBL%N2J5*KX$ M$DN&P<.]R_+LM48 *^=Y7YV:W#Z[@^W%!/U+)CY=:I'FT6J)@5F*19J'\9K= M4_L4L1E/9F*GK5B>_=JVDD7OS2U_3TE+<*4BN(%I!&>>*K&,44/&>.W:ACKF M(J?K[+;M>&'T%+'/6@<&RF)ZW[/HD7M' MP5O<*7-Q_?]@FI/8;,DU66DK)0 MDDS\:MV:1DX63>:@R9I'-C*Y%TE[VPW6K);6L)C+K=:CS%%1M&T:BLR37):4 M,@4G3T\W1.M)$CPTVC([:KVW):&6RC.)P7A"+9&8-$.L/D.=&C MS-E_V9FT.+"XK=YY#DR>',B,+*R@4)0'6BVTMO/:P 6BU3S):,GOF7I_F+M? MLI4G1B.TY_3-0:DU\8J(?KGF1[_N0B%+7\RC<)1XL4":&UT_^E6@WL];Z/-9 M/M<9 K9P?[@XW%PU]ZO"1E?A)%2HB+/=L4WF\58W=ZGE"["YM8<,NT55'%I^ M8@$;\Q@V)^(",V#^&)=R[+AIG-F,,J:/I:&BDFOL_R=!S=M][H- M2*S54T@4R%RKYX\YPPHIP82P;UBK],P#OI(Z'8/.5>\QVJA/+MNG919RS)-. MEH@R$)&-ZQJ+G.'@NLTRK/5C8SX'K!\_%+LU*>I[:-T?-LTYM+9Y")= :;O3 M+05*S1.#EO2>27J=DI">16GVJA.MH6.0BK VG9$1K<*:;KX;8;L;-B+A?@OO MHFMZZ=[<;F&]-HLT5YHY=(;UV:^)F+8IB#%/NEH".DU +5/(QZ)E'2W-/'GJ M-@QW;9/M0./3 WW\,O:K&[S*.J%>7NT: [::EV@,V'.7@+:- 0]UK%O:[.]I M%(!4$>03]JR;THB17Q,^PBYNE6T2N&J%JF^* M_,D\Q%? TG(IA,9QQ!\2U?XN#LG=O^[)WQGUXRG^M7J$IK@^_1RV/ 7=X27^ MOG?_^N[=)S+B*$N <#[=R^&KGU'$B+TR+Q(\%F=$%+' \!EJ& M*0 9U/<79!R%,Q)/0\'DLM@,I#ZN\V$AFQ0>6P$V,J0D2&8/,"4 UL1(URH M("/9K/A!PI6$"7#/^SML6HS:;H#1 MR.< '0E#+F3':* .YF.':+E0>%L0QHR Y4L0RX?&XG)G(4B[=6S#_Z;A$WEB M2R9@&U3MD/RR)+,(*F$_R[X#^#SX\_D](H?-%^EGV1_:M99HK=EZ6CZW_V++ M?;7%:YI[3@;-#6\@]'\@++$Q(ZJ"GT'82Q66RMX\3?].@G"X#<$JM!S[$#Z] M>*^V2@+N[_#Y'/+*>-A1HM:'RMQ9]C]4?ZHFB.HS6$CJ@T#'2WVDLS )CER* MRDE[Y: 96?8(#:6[< :[7-@NB>= $5QX#<-9&. GZ<]G@&4]P66)[DI$5X>F M@+]GBLN\EB[N##S0)&*7R^BH=)N8?)LWNRS"L-$Z]X9@YKZF1=92MQ1<=0KN M.<.\19$M 5L"-F?7PT9G8$6PI>#R4G#?<8T4P5?*=BW6S$^/J=2AJCY=.[-84*#N'.7/4K)'=NUD(B_F//A\=@X\;TV#"T;6E0K BJC<5VQ.D,>CGO>5L M>UY=&TE.YZJ57BR.+"-5$TF%,E+-FJ)]8!/J8Z)8[*O<+NIY44+]FO5%R^^> M/RM!OJ3%8PM%4=-IY^W'8G%DVF-0MIO>XW<[2:M'[XM='3=+K7JK-C\6/9IVKH*8Q]K,%B MBL'RS!L;Q=6:"A4UTMB1LP*X'3NZ& M(I: +0&;LVO7;;CG)KE9$K8D;,"N!T['2 +6'DJZBG3-74F>!=P56-MM&[8T M"A/T(,XI#6!76=E5UJ$0PO_*/[#L)*R*3MBR8*2L<2-(F,0BIK(LU5EWIK(> M:=MC\<.9]^UVA3+O39G#$LM+)5'LE.-.7ZW?<(-"\(T[F!^IQ)RA?+&MQKU9 MC=N]2#7NSJNWMAKWB4+6[U716G%ADMVL!MO>%#4O5/$Z2T"[]:S^/.1E(O$Y M2G7K>F%DQ,;PNU@5V%XU0$J/$\3N=YLUH C[MBH4S=;2)NBIB[>J+C,\%!$> MLQG6G(:G@D4#)J(Q"1B7OTGXRK,,G!]L5BXK2'MA$@F&$\>K'6&99;=_*\A# M(G!G@@0ASC#V&2QJWT!5[W"!RU\^ QN6)94#CS6(2+PI@@$?9@(%.1=3>;L) M7JU+>1/_P,TGV!-VDF('$[)Q3LPFJB8C;%7$PB'KF$O$ M*;3Q&"M&P]]\#DO3V,(U"S:12US;I1I/6##%O\1>0-$'[O-X@7CP\">8;$Y% M3,;+"P/IA$L I3OBB&/P M7A@(%9"XJIHY@!\(9;42E;X3H T?)@!^?.)!3976)BL*G]TJ?C"%+#X[<;@@]3GY)#G^AL4G<-*B/=6P>)] MHX5-T[2B=#%T=1,:V$58U74XU M-;+I)26EI70&:2_FH2K8K7$5TV\@: - >8P"E7V;LP! D\ZF(;=/,&4G#[,$ M:C9"W1*L>3:;4;HVG4K*UU6>5A'2E>R59$@*2PRR\1A[H3RR=1:(4$RDG'IP MP%'IMU^ K,/G"1Z:$=T!C;3XR"D)G3THT*AOV2/TD7<#2(B-/4R;%)04= M(;R(Q6S].6V2@3DVHZ.E,#T-3X?\G$0I=.)IQ- \"^*I.-RPI;'?LLV .E^$ M*1S%EC))!>UR;_B4@CRV05*@USUSQCP" U)WF,&'91N9>G-TIV"._LA&N+ E M.TGEMF4Z >NF/RNE)PTI95.![ICQ9 :\]\B"A"F%&#%4*7A30.(=U#:&/=!, MD@VIMIX0%MRS%/$I36/AE&L7R5'S*-PE'@Q6 YRG#3OR".-N/(:'UC\Q!@Z M7QLMK613(Y!/LL76^I< P )5OMXR".JX](-B)WH1G=?TD\XP H0[]LE: M;E=.%3R" 82-J*2[MZZQ 1KCQ)=.H81%*C%67DNZI@/V6@IJ+13OT//]*<5/ M"I*ZJ^6N(4RL^6'*Y]LLN&J!IL< )S]*U_^ @Y/B'>GKW?W=DC=3E&L^5P(" M%O[(D0G .Z#(SQX?<_A^'G)4C2#].7K^VUPJC<\9 PWL(;=F8:O9[DXW.$RW MWT"1]<1\7UH=F?CKR]I:GL5GJUWL>EY[5@_/IB&I&!L:; K2'3:M.Z?UBC: M)8[FX.3/J >^KD_Y3,I!H%7!=C3?BNWP:R_B<^4Z;C\&!ER83*9[.7'YLJ5: M5&0920K!]'\T?B4C:\<6RN3&!_T;B87%E?MI8L%QKOMS>: M5P356P+U"PYQ_A9H/XP&ZWZD/)@(<-EDV+P9T<46F6O'DOV5<'!3=91,^8WM M/>.U0EQ[@8[5*:X?4QFUH[%FR\UWJ>:I0']SH/=O'%NY^@O]LEC"0OJXDJ5T MBUJT*0BL0N"IP]Q'XT&?LTAOFF*X<";-C]6+G,*N]#R#?@[K[_IE*+0.9RB8 MEVQ0"^$V*-B\^I3JL=1NX4+'&6440JMS;8G0.+5R-DT8_>7*F-ALY[QK8>T\ M("?TPV!R@T$\XLGCWK7I'I)X+3[Y$=M9LT &">ZF(<=H BI7'H-R?9IR;XK; MX&DP#%6\#HA)^\M3CW@@)2=AM'#VS3?'6"+(7L"3.JCQ0$3BV;)/@Z5'!W(2 M(8,SB#EL MNN7@A6]$*ZETOWB X3P8D ;/Z0C\*Q2G!X+IA[?D\S3#[,CF9/;8[IN]*0TF M3$8B5$[$D.;45"MN*Q/AX7H46 M()+-FL\L\&+>R-$O4(@[P5?;;YJLKPT&XUOVQ(&.GNEMC9>1@8BA"0H/H]>& MUD$22993"81I^HP0(1@*L;:+]RYP8ZO*UD^M%1U/VP; ,H!_)+ FUSBC&%9] M_BG9KAV%R]P?[:Q[ ,UM%722[B51^7GK6Q"8IR*]4E!! M$6I0(%VE;8&2P=T,$)O^0@7UP.^#EZ>. >4J#CYB7L2H4+FR0I_?:T\U=5*5 M*)%FIP?T&\[D^?U+G;XM0_3YSMCJKBZ+3C.[Q]B""C=@+J8X=)*Q4DHJ24P: M0HCN#03O]8AT!.:X1[10B] *;0I6)6@+X)(5R2"%3X#H8^DU@646!HPL&(T: M>'84Z4,G6,>ZPI2S:1,N3:@*).M@&FW*1CJ?#1UJ';Q?R[B?R\1\==CDK,,K M/6G2Z5HK2,CTMX\\2&)V)[FYU%Y<$72I1-=APD( HY[7U"%/44Z>8FX(\O6$ M)#3^OW$AJ4Q3(:8JKQ,!P(7K#.10RT,R3F2J(M 0%W)9JYS=[>GPP0! XX=> MNEPDI)M-0CKWR%+E'NX]MYQC_KG*/4\OR1R!JY+*DMD0PF$TH4"]:+8^J53B MY;Z6&R% 0"(1&R_;G@94/_Z! %#P..(DU>]HIGWX:.9O#^%H ?\WC6?^V_\' M4$L! A0#% @ ]#.D5(74X!6J% (X, ! ( ! M &-V&UL4$L! A0#% @ ]#.D M5 ]]&">M!@ Z3 !0 ( !'C$ &-V&UL4$L! A0#% @ ]#.D5)8EVH!R@0 4_\) !, M ( !_3< &-V#DY>#%Q,2TR,BYH=&U02P4& 8 !@"" 0 H+D # end